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enigmatic ever since. A little later Robert Koch stained bacteria and enabled the first 
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production and giant cell formation associated with granulomas. However, difficulties with 
developing a mouse model for granulomatous auto-inflammation have limited in vivo studies. 
Because of the Genetic Revolution, we are now able to identify extra-ordinary mutations 
associated with rare orphan diseases. Increasing attention is given to orphan diseases, which 
only affect a small amount of patients globally. By chance or increased mutagens in the 
environment there are some de novo mutations occurring in human germ cells. These 
mutations occur occasionally in genes responsible for crucial functions. The nucleotide 
oligomerization domain 2 (NOD2) protein is crucially involved in innate immune function, 
one of the most evolutionarily conserved parts of the human immune system. Extra-ordinary 
mutations can abolish (knock-out) or alter, either enhancing (gain-of-function) or disrupting 
(loss-of-function), a specific gene function and create rare phenotypes. In the Blau Syndrome, 
gain-of-function mutations in an intracellular pathogen sensor protein NOD2 are believed to 
cause granulomatous auto-inflammation i.e. the automatic formation of granulomata or 
grain-like collections of white blood cells. The Blau Syndrome can serve as a naturally 
occurring study model for granulomatous auto-inflammation to gain insight in various known 
idiopathic granulomatous diseases, to aid in the development of relevant animal models and 
to define pathogenic mechanisms for therapeutic targeting. The pathological enigma of 
granulomatous inflammation in children and adults was investigated by us through detailed 
observation of Blau Syndrome patients, a Chronic Granulomatous Disease patient and a 
Cartilage Hair Hypoplasia patient as immune-pathological study models for granulomatous 
inflammation. In addition there will be a comparison of genetic, pathological and clinical data 
between a selection of pediatric and adult sarcoidosis and pediatric Crohn’s disease patients. 
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GENERAL INTRODUCTION       
1. WHAT IS A GRANULOMA? 
Granulomatous inflammation was described for the first time in the early nineteenth century 
and has remained enigmatic ever since.
1
 It is characterized by chronic inflammation and the 
presence of inflammatory nodules in the affected tissue. Granulomas are focal compact 
collections of inflammatory cells, predominantly of the monocyte-macrophage lineage 
(MML), which can result from the persistence of a non-degradable antigen (non-immune 
foreign body granulomas primarily made up of multinucleated giant cells (MGCs)) and cell 
changes of active cell-mediated hypersensitivity (immune granulomas that predominantly 
consist of epithelioid macrophages).
2 
This inflammatory response intends to protect against 
chronic infections through activation of cell-mediated immunity.
3
 Different characteristic 
histopathological features can be useful to determine the etiology of immunologic 
granulomas: (caseating) central necrosis is typically associated with intracellular pathogens 
(e.g. mycobacterium tuberculosis) and eosinophilic granulocytes with sclerosis are typically 
seen with extracellular parasites (e.g. schistosoma mansoni).
2 
Granulomas without 
pathognomonic features are associated with several non-infectious immunologic insults such 
as cancer and drugs and can occur in immune deficiency (ID) as well.
2 
Differential diagnosis 
in early stages of granuloma formation is difficult because characteristic features only appear 
in the terminal stage of granulomatous inflammation. Granuloma formation and persistence is 
even more enigmatic in clinical disorders in which no causative antigen can be identified, 
such as sarcoidosis. It is well possible that in this context, the granuloma is a consequence of 
an intrinsic cellular/molecular defect concerning immune-inflammatory homeostasis. Cluster 
of differentiation (CD)4+ T cells emerge as the central mediators in the initiation, 
accumulation, effector and terminal stage of granuloma formation.
3 
A distinction between 
low-turnover and high turnover immune granulomas can be made and will be referred to as 
hypo-inflammatory and hyper-inflammatory granulomas in our research, which focuses on 
NOD2-related non-infectious granulomatous inflammation.
4
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Like the ancient Roman god Janus, the granulomatous inflammation has two faces looking in 
oposite directions: it is intended as the ultimate immune defense against chronic infections, 
but can cause irreversible tissue damage in the process. According to Adams DO, several 
definitions of a granuloma are possible: a) a focal collection of mononuclear cells including 
lymphocytes, mononuclear phagocytes and plasma cells; b) a focal collection of mononuclear 
phagocytes alone which has maintained that appearance since its inception; c) a focal, 
organized collection of mononuclear phagocytes; or d) a focal organized collection of 
mononuclear phagocytes containing epithelioid cells.
5
 The first definition does not 
distinguish granulomatous from chronic inflammation and can be used to define a 
mononuclear aggregate. The second definition does not take into account that a granuloma is 
an organized immune response that requires functionally specialized cells such as epithelioid 
macrophages and multinucleated giant cells (MGCs). The fourth is therefore unnecessarily 
restrictive, excluding foreign body (FB) granulomas. In the FB granuloma, the specialized 
MML cell type is the MGC, while the epithelioid macrophage has this role in the epithelioid 
granuloma. These two morphological appearances do not exclude each other and there exists 
a wide spectrum of mixed phenotypes. The third definition permits histological distinction of 
a granuloma and therefore is adopted in this thesis. This definition describes the granuloma 
well in theory, but in pathological practice additional features enable distinction between 
different granuloma progression stadia and etiology. We have to define the granuloma 
unambiguously for qualitative and quantitative pathological scoring of morphological 
features and immunohistochemical (IHC) profiling. Therefore we modernized the adopted 
morphological definition for this doctoral thesis by adding IHC markers
6, 7
:  a granuloma is a 
focal, organized collection of CD68/KP1+ and human leukocyte antigen (HLA)-DR+ 
matured MML cells detected by light microscopy and comprising at least 5 epithelioid 
macrophages or 2 MGCs. The terms ‘focal’ and ‘organized’ are essential: focal meaning 
localized, as opposed to a diffuse inflammatory infiltrate, and organized in the sense of 
attempting to confine an antigen and wall it off from the rest of the body mechanically. 
Functional organization requires morphological changes and regulation by CD4+ T- cells.  
15 
 
1.1. The monocyte-macrophage lineage in granulomatous inflammation. 
From a phylogenetic point of view, phagocytosis by mononuclear phagocytes is one of the 
host’s most primitive defense mechanisms.8 The MML is part of the innate immune system 
and consists of phagocytes and their progenitors. In the bone marrow, monoblasts are the first 
developmental stage of macrophage maturation from pluripotent hematopoietic stem cells. 
The promonocyte is the last developmental stage in the bone marrow, before the monocyte is 
released into the circulation. Monocytes will then enter the tissue in response to inflammatory 
signals or to replenish resident histiocytes. Most of the mononuclear phagocytes derive from 
monocytes, though a few are local histiocytes.
5
 Histiocytes or tissue macrophages comprise 
two functionally distinct cell types: the macrophage specialized in phagocytosis and the 
dendritic cell specialized in antigen presentation.
5
 Histiocytes are morphologically 
characterized by oval euchromatic nuclei, abundant cytoplasm and prominent ruffles and 
pseudopods.
9
 MML cells have the potential for pinocytosis and phagocytosis, adhere strongly 
to glass, migrate by ameboid motion and present receptors for activated complement 
component 3 and activated crystallizable fragment region of antibodies.
9
 MML cells actively 
synthesize protein that is either packed in the Golgi to accumulate in lysosomes (lysosomal 
hydrolases) or secreted (interferon(IFN)-α, tumor necrosis factor(TNF)-α, Transforming 
Growth Factor(TGF)-β, macrophage inflammatory protein -1α, interleukin(IL)-1, IL-6, IL-8, 
IL-12, transferrin, endogenous pyrogen, complement components, lysozyme, acid hydrolases, 
neutral proteases,…). Another term of Adams DO will be adopted here: mononuclear 
maturation. Mononuclear maturation comprises all functional enhancement (epithelioid 
transition or MGC formation) of mononuclear phagocytes (circulating monocytes or resident 
histiocytes) and occurs after contact with stimulants such as certain anionic molecules, 
nucleotides, anti-macrophage antibodies, cytokines, digestible substances, endotoxin, lectins 
and pathogens.
4
 It is relatively stable, requiring several days to occur or resolve.
10
 
Mononuclear maturation can induce aggregation and microgranuloma formation.
5
 When 
evoking a granuloma, the irritant stimulates mononuclear maturation through persistence 
(resistance to degradation), through its particulate form, due to high local concentration or 
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resulting from (innate) immune memory and hypersensitivity. This initial or repeated, 
localized contact attracts additional monocytes from the blood and histiocytes from the tissue. 
Higher virulence of the antigen will induce intensification of maturation and enhance 
epithelioid transition, MGC formation and the overall cellular turnover in the granuloma 
(Figure I.1A). Epithelioid macrophages and MGCs are both specialized MML cells that are 
better equipped to cope with a challenging opponent. Dannenberg et al have demonstrated 
that epithelioid transition is associated with destruction of ingested mycobacteria.
11
 
Epithelioid macrophages have increased synthetic, phagocytic, bactericidal and degradative 
capacities in vitro and interdigitate to wall off the inciting antigen from the surrounding tissue 
(Figure I.1B).
9
 In an attempt to swallow an indigestible exogenous particle entirely, MML 
cells can fuse during mononuclear maturation to form MGCs (Figure I.1C). MML fusion has 
been shown to be mediated by IL4 and CCL2 in vitro.
12
 Maturity differences between MML 
cells do not restrict cell fusion: fresh circulating monocytes, resident histiocytes and fully 
matured epithelioid cells fuse with each other and existing MGCs at the focus of 
granulomatous inflammation. The nuclei and organelles are intermixed and diffusely spread 
throughout the MGC in a disorganized fashion. They can mature further into Langhans type 
MGCs after microtubule-mediated reorganization of their cytoskeleton that results in their 
characteristic peripheral nuclei, central scant cytoplasm and ordered organelles.
5
 This is why 
they can be found in both foreign body reactions to a non-toxic antigen (MGCs don’t die 
from toxicity) and non-infectious sarcoid granulomas (MGCs don’t die from infection). They 
can be frequently observed in other granulomatous diseases and the majority of low-turnover 
(hypo-inflammatory) and high-turnover (hyper-inflammatory) immune granulomas.
4 
Although Chensue SW focusses more on the role of chemokines in innate and adaptive 
granuloma formation, his terminology is at least as useful to distinguish between ‘dry’ and 
‘juicy’ granulomas i.e. the absence or presence of additional immune cell types and 
accompanying etiology-associated features that might be characteristic for certain 
granulomous diseases, if compatible with the clinical diagnosis and classification of the case. 
17 
 
 
Figure I.1. H&E A) Acute inflammation (neutrophils & monocytes) can turn chronic (monocytes & 
lymphocytes) if the insult persists (x1000) B) Epithelioid microgranuloma of a granulomatous 
dermatitis patient (x1000) C) FB type microgranuloma found in the connective tissue of the ear (x400). 
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1.2 Different phases of granuloma formation defined by Co et al in 2004 
During acute inflammation to an antigen, a predominantly neutrophilic infiltrate is formed. 
As the inflammation turns chronic, the infiltrate becomes dominated by mononuclear 
monocytes and lymphocytes instead of polymorphonuclear (PMN) granulocytes (Figure 
I.1A). This transition takes place because the neutrophilic granulocytes have the capacity for 
phagocytosis, but are not specialized in it like the MML cells. Granulomatous inflammation 
is a special type of chronic inflammation associated with focal aggregation and maturation of 
MML cells. The process of granuloma formation can be divided into four phases: the 
initiation, accumulation, effector and resolution phase.
3
 
 
1.2.1 The initiation phase 
During the initiation phase, the basic structure of the microgranuloma is established through 
recruitment of monocytes, the expression of chemokines and adhesion molecules and early 
mononuclear maturation. Histiocytes are a natural choice for the central mediator of 
initiation, since they are part of the innate immune system and already reside in the tissue 
close to the inflammation site before specific antigen recognition has taken place. Hence, the 
MML seems to stimulate its own maturation: circulating monocytes arrive at the site of 
inflammation and establish themselves close to an activated histiocyte. On this moment they 
lose S100A8 and S100A9 expression and there is a shift in gene expression profile.
13
 
Morphologically, these freshly arrived monocytes appear to be more swollen and their nuclei 
have a more irregular shape. Furthermore, it is widely believed that frustrated phagocytosis 
plays a key role in the initiation phase. Naïve T-lymphocytes and natural killer (NK) and γδ T 
cells may also play an auxiliary role during the initial contact. Aggregation of the initial 
inflammatory infiltrate is induced by IL-1 and TNF-α production by the MML and possibly 
NK cells.
3,14,15
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1.2.2 The accumulation phase 
In the accumulation phase, additional MML cells are recruited by chemokines and adhesion 
molecules to destroy the pathogen and strengthen the structure of the microgranuloma into a 
mature granuloma (Figures I.2C and I.3A). In this phase, CD4+ T cells play the central 
mediating role by enhancing the auto-stimulation of the MML cells that make up the mature 
granuloma.
3
 In the light of the archaic Th1-Th2 hypothesis, granulomatous inflammation was 
polarized between Th1 granulomas characterized by enhanced expression of CXCL 
chemokines and Th2 granulomas by enhanced expression of CCL chemokines.
16, 17
 In 
keeping with the Th1-Th2 theory, discribed distinctive chemokine profiles to innate and 
adaptive granuloma formation in mice infected with antigen carrying beads.
17 
The delayed 
hypersensitivity reaction to mycobacterium tuberculosis, represented by the experimental 
model of Purified Protein Derivative (PPD) inoculation, was the prototype for Th1-mediated 
granulomatous inflammation with the activation of MML cells  to defend against intracellular 
infections via acidification of the phagosomal compartment and the production of NO and 
Th1 cytokines such as IL-2, IL-12, IFN-γ and TNF-α.3,18-23 Tuberculoid granulomas are 
characterized by the presence of central caseating necrosis. Schistosoma mansoni  infection 
(Figure I. 2A), and its experimental inoculation with unfractionated aqueous-soluble 
constituents of schistosoma mansoni eggs (SEA), on the other hand, was characteristic of 
Th2-mediated granulomatous inflammation with recruitment of eosinophils, marked fibrosis 
and the production of Th2 cytokines such as IL-4, IL-5, IL-10 and IL-13 (Figure I.2B).
3, 14, 24
 
This way of looking at granuloma formation is much too simplified, as demonstrated by 
many experimental findings contradicting predictions based on the Th1-Th2 hypothesis.
25
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Figure I.2. H&E A) Schistosoma ova cyrcled by epithelioid macrophages (x400) B) Epithelioid 
granuloma with eosinophils flanking a schistosoma ovum (x400) C) Epithelioid macrophages, MGCs 
and T-lymphocytes in the lung of a TBC patient (x400) D) Central caseating necrosis palisaded by 
epithelioid macrophages, associated with few MGCs and lymphocytic corona in a complex TBC 
granuloma (x200). 
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1.2.3 The effector phase 
In the effector phase, antigen-tailored regulatory and effector immune cells are recruited to 
the mature granuloma. Different leukocytes such as T, B and PMN cells are attracted for an 
immune response tailored to the inciting antigen.
3
 Attracted cells cloud together around the 
mature granuloma and project the 2-dimensional image of a corona upon morphological 
investigation of a tissue section, hence coronal granuloma (Figure I.3B). Recruited 
regulatory cells secrete cytokines and effector cells execute their specialized functions to 
defend against a specific intruder: epithelioid transition to confine the pathogen and isolate it 
from the body, fusion of MML cells to MGCs to attempt to swallow an inert particle entirely, 
degranulation and cytokine production  (IL-1, IL-2, IL-4, IL-5, IL-6, IL-8, IL-13 and TNF-α) 
by eosinophils, apoptosis induction in infected/dysfunctional somatic cells by 
Fasligand(FasL)+ CD8+ cytotoxic T cells and antibody production by B cells.
3, 26
  
 
1.2.4 The terminal phase 
The terminal phase has two possible outcomes: resolution or chronic persistence. Resolution 
starts when the pathogen is defeated and the antigenic insult is removed. The subsequent 
downregulation of granulomatous inflammation from a high turnover coronal granuloma to a 
low turnover mature granuloma and eventually to dispersion of the inflammatory infiltrate 
and fibrosis is mediated by regulatory T cells, γδ T cells and cytokines such as IL-10, IL-13 
and TGF-β. During resolution, sclerosis appears around the resolving granuloma, hence 
sclerosing granuloma (Figure I.3C). Possibly, the remaining macrophages can return to a less 
mature phenotype to become regular histiocytes again and disperse during resolution (Figure 
I.3D). IL-10 downregulates macrophages and inhibits antigen presenting cells and Th1 
polarization of CD4+ cells, suggesting that Th1 is important in granulomatous 
inflammation.
3, 27-33
  The terminal phase of granuloma formation is associated with chronic 
persistence and the inability of the granulomatous immune response to confine and destroy 
the insult. This can be considered the end-stage of the disease. Tissue destruction can be 
22 
 
maximal if caused by both the insult and the granulomatous response in a disorganized 
fashion, resulting in a complex granuloma with features of cell death (Figure I.2D). 
 
 
 
 
 
Figure I.3. H&E Synovium Blau Syndrome (BS) A) mature epithelioid granuloma with central MGC 
(x400) B) coronal granuloma with central MGC (x400). Sirius Red Liver NOD2- Pediatric Sarcoidosis 
(PS) C) sclerosis inside and around a polycyclic granuloma found in the peculiar isolated hepatic 
sarcoidosis patient before corticosteroids as published in the case report in Results Chapter 3.3 (x200) 
D) after corticosteroids granulomatous inflammation resolved completely, leaving scar tissue (x200).  
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1.3 Histopathological criteria for classification of granulomatous diseases 
The large family of granulomatous disorders comprises numerous infections (such as 
tuberculosis, leprosy, Yersinia, listeria monocytogenes, pneumocystis pneumonia, 
schistosomiasis, cryptococcosis, histoplasmosis, cat-scratch disease, etc), vasculitis, 
immunological aberrations, leukocyte oxidase defects, hypersensitivity, anorganic 
compounds and neoplasia. Differential diagnosis demands a skillful interpretation of clinical 
findings and histology.
2
 The most important histological features of granulomas and their 
interpretation, the accessory features of complex granulomas and rare subtypes of complex 
granulomas are described here. The exact pathogenesis of many rare granulomatous diseases, 
such as primary biliary cirrhosis (Figure I.4), remains unclear. An auto-immune targeting of 
bile ducts is suspected: their destruction causes cholestasis in the liver and eventually 
cirrhosis and liver failure. In daily pathologic practice, the differential diagnosis with respect 
to etiology relies on a limited number of histologic features, most importantly: the presence 
or absence of caseation and necrosis (often seen in infectious diseases), inclusion bodies and 
vascular involvement.
5 
 
 
 
Figure I.4. Primary Biliary Cirrhosis A) IHC Keratin (K) 7 Auto-immune granulomas targeting K7
+ 
bile 
ductules in the liver (x400) B) H&E serial section, without highlighting of ductules by K7 IHC (x400).  
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Disease Caseation Necrosis Inclusions Vascular changes 
Sarcoidosis absent rare present present 
Crohn’s disease absent absent (?) present 
Tuberculosis present present rare rare 
Fungi absent present rare present 
Extrinsic allergic alveolitis rare rare rare absent 
Foreign body  absent absent present absent 
Xanthogranuloma absent absent present absent 
Leprosy absent present absent absent 
Brucellosis absent present absent absent 
Yersinia absent present absent absent 
Primary biliary cirrhosis absent absent absent absent 
Cat scratch disease absent present absent absent 
Wegener’s disease absent present absent present 
 
Table I.1. Some of the most common granulomatous diseases and their main features are listed here. 
(?): not known to date. 
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1.3.1 Common features of granulomas 
Distribution: the extent of granulomatous inflammation in a certain tissue can be described in 
terms of focal, diffuse and polycyclic granulomatous inflammation. Focal granulomas or 
solitary granulomas are likely to be FB type granulomas that result from a single isolated 
insult by a granulomatogenic particle. Diffuse granulomatous inflammation is characterized 
by the presence of more than one isolated granuloma and can indicate either several particle-
mediated isolated insults or the onset of more severe granulomatous disease. Polycyclic 
granulomas or granuloma-in-granuloma complexes are characteristic for more severe 
granulomatous diseases such as tuberculosis, because they reflect the persistence of an insult 
associated with the presence of extensive granulomatous inflammation in the affected tissue.  
Epithelioid macrophage vs MGC predominance: the predominant type of MML effector cell 
that is present in the granuloma reflects the severity of the immunologic insult, as described 
earlier. If there is a minority of epithelioid macrophages, the virulence of the evoking agent 
tends to be less. Some representative evokers of chronic inflammation (no granulomas, no 
epithelioid macrophages) are simple delayed hypersensitivity, carbon, fibrinogen, Salmonella 
paratyphi and carmine; of FB-type mature granulomas are inert particles, lipids, high 
molecular weight polymers, delayed hypersensitivity to particle-bound antigens; and of 
epithelioid mature granulomas are Mycobacterium tuberculosis, granulomatous 
hypersensitivity, Blastomyces dermatitidis, Treponema pallidum and Chlamydia 
trachomatis.
5
 
(Langhans type) MGCs: MGCs often contain inclusions of digested antigen that can possibly 
convey histological information about the etiology of the granulomatous disease. The 
presence of Langhans type MGCs (Figure I.5) with their typical peripheral nuclei in a 
horseshoe pattern suggests the MGCs had time to mature and reorganize their enormous 
amount of cell content. This means the evoking agent probably is an inert particle that is 
indigestible and persists without actively exhibiting cytotoxicity. FB MGCs are formed by the 
fusion of epithelioid macrophages and other components of the MML.
12
 They will not survive 
long if they suffer from the cytotoxicity of the infectious agent and therefore did not have 
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sufficient time to reorganize their organelles and nuclei and obtain the typical appearance of a 
Langhans type MGC. Next to necrosis due to high virulence pathogens, MGCs can die due to 
programmed cell death such as conventional apoptosis or alternative caspase-independent cell 
death (CICD). Different types of cell death can be distinguished morphologically. Apoptotic 
bodies or ‘nuclear dust’ resulting from nuclear fragmentation (karyorrhexis) are indicative of 
apoptosis and not CICD.
 34
 The presence of micro- and macrovesicles in the cytoplasm are 
suggestive of autophagy-induced cell death (Figure I.5A). Other forms of CICD include 
caspase1-mediated inflammatory cell death (pyroptosis) or programmed necrosis 
(necroptosis) related to death domain containing proteins.
35, 36 
 
Inclusions and bodies: in or outside MML cells in granulomas appear to be more than the 
subject of a pathologist inspired by Serendipity and pays attention to inoccuous details: 
 
A) Asteroid bodies are stellate inclusions in MGCs with numerous rays radiating from a 
central core. They can be seen in both sarcoidosis and FB reactions. Structures strongly 
resembling asteroid bodies may be seen rarely in the cytoplasm of tumor giant cells and in 
fibrin-rich exudates. They are thought to represent cytoskeletal elements and consist 
primary of vimentin. They are related to centrioles, an organelle involved in cell division 
in eukaryotes.
37, 38
 
B) Refractive crystalline inclusions composed predominantly of calcium oxalate, are 
frequently found in the MGCs of granulomas of sarcoidosis and other diseases. They are 
believed to serve as the nidus for calcification that results in the formation of conchoidal 
or Schaumann bodies.
38, 39
 
C) Conchoidal or Schaumann bodies are large concentric calcifications often containing 
refractile calcium oxalate crystals. Although usually intracytoplasmic they may be 
extruded into the extracellular space, if numerous or very large. They can be found in 
Langhans type MGCs of berylliosis, sarcoidosis and hypersensitivity granulomas.
 38, 39
 
(Figure I.5B) 
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D) Hamazaki-Wesenberg bodies are yellow-brown structures found in lymph nodes that can 
mimic fungal yeast forms. They may occasionally occur as inclusions within MGCs, but 
are usually found extracellulary in the sinusoids of lymph nodes with or without 
granulomas in sarcoidosis and other conditions. The pathogenesis and significance of 
Hamazaki-Wesenberg bodies are unknown. Ultrastructural studies have shown that these 
bodies are giant lysosomes and residual bodies. These bodies may represent lysogenic 
mycobacterial products. Their ultrastructure and histochemical staining characteristics 
have been reported to be similar to those of lipofuscin. Reports that the bodies show acid-
fast staining with Ziehl-Neelsen stain indicate a relationship to ceroid.
40-42
 
E) Lysosomal inclusions of micro-organisms in (epithelioid) macrophages and MGCs can be 
detected by PAS staining (fungal and intracytoplasmatic micro-organisms) or specialized 
stainings for acid-fast bacilli such as mycobacteria (the auramine-rhodamine staining or 
Ziehl-Neelsen staining).
43, 44
 
F) Slit-like cholesterol crystals can be seen in MGCs (of xanthogranulomas).
45
 
 
 
 
 
Figure I.5. H&E Spleen BS A) Langhans MGC with nuclei in horseshoe pattern and morphological 
features of autophagy-induced MGC death i.e. pyknotic nuclei in hypereosinophilic cytoplasm with 
micro- and macrovesicles (x400) B) Schaumann body in the centre of a healthy Langhans MGC (x400). 
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1.3.2 Accessory features of complex granulomas 
Presence and type of PMN granulocytes: Interstitial and parenchymal inflammation and the 
composition of the inflammatory infiltrate around the granulomas can give the pathologist a 
clue about the etiology of the granulomatous disease as well.  Suppurative granulomas are 
characteristic findings in lymph nodes in cat scratch disease, lymphogranuloma venereum, 
and tularemia.  They are granulomas with pus and central micro-abscess formation that 
consists mainly of neutrophils. In these conditions the granulomas are often large and 
irregular in shape and may exhibit a stellate configuration. Eosinophilic infiltrates around the 
granulomas are characteristic for parasitic infectious granulomatous diseases such as 
schistosoma mansoni infection.
14
 B cell and basophil recruitment to the site of granulomatous 
inflammation is minimal and probably a side-effect of the inflammatory cocktail of cytokines. 
Presence and type of sclerosis: If the inciting agent is defeated, the resolution phase of 
granulomatous inflammation is initiated and fibroblasts are recruited to transform the tissue-
damage caused by the granuloma into scar tissue. Presence of sclerosis indicates the 
granulomatous inflammatory response is successful in combating the antigenic stimulus and 
is characteristic for the partial recovery phases during granulomatous schistosoma mansoni 
infection or the typical smouldering sclerosing aggregates in classic pulmonary sarcoidosis.
14 
Presence and type of necrosis: necrosis is a feature of complex granulomas that can indicate 
the nature of the immunologic insult responsible for granuloma formation. Non-necrotizing 
granulomas are characteristic of sarcoidosis, beryllium disease, hypersensitivity pneumonitis, 
tuberculoid leprosy, (paediatric) Crohn's disease (pCD), etc. The presence of non-necrotizing 
granulomas is generally indicative of a non-infectious etiology. However, the finding of non-
necrotizing granulomas does not exclude infectious etiology. Coagulation necrosis or 
fibrinoid necrosis can result from a local infarction secondary to the granulomatous disease 
and needs to be distinguished from infectious liquefactive necrosis as a primary consequence 
of the granulomatous disease. Signature necrosis such as caseating necrosis in mycobacterium 
tuberculosis granulomas (Figure I.6) and gommatoid necrosis in treponema pallidum 
granulomas are good examples of infectious liquefactive necrosis, while necrotic neoplasms 
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and Wegener’s granulomatous vasculitis are good examples of non-infectious granulomatous 
disease exhibiting coagulation necrosis. Confluent necrosis results from necrosis of 
polycyclic granulomas bridging to each other and forming complex labyrinths of necrosis. 
Confluent necrosis is associated with the end-stage of the disease and indicates the inability 
of the granulomatous inflammatory response to confine and destroy the evoking agent.
5
 
 
 
 
 
 
 
 
 
 
Figure I.6. H&E TBC A) Confluent (caseating) necrosis causing massive obstruction in the lung (x100) 
B) Discrete (coagulation) necrosis in the centre of a granuloma in the infected lymph node (x200).  
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1.3.3 Rare subtypes of complex granulomas 
Complex granulomas can be accompanied by pathogen-induced or idiopathic histological 
properties that are unusual and can be pathognomonic: 
Xanthogranulomas: are granulomas formed in response to lipids. The MGCs that are 
consequently formed are called Touton MGCs and they are characterized by a ring of nuclei 
around a central eosinophilic zone. Furthermore, they contain many ingested fat vacuoles that 
appear as zones of pallor extending to the periphery of the cell.
45
 
Fibrin ring granulomas: or doughnut granulomas characteristically contain a ring-like 
structure consisting of fibrinoid material with or without centrally located fat vacuoles. This 
uncommon type of non-necrotizing granuloma is frequently observed in Q fever (Coxiella 
burnetii) and may be seen in infectious diseases, such as Cytomegalovirus, Epstein-Barr 
Virus, Mycobacterium avium -intracellulare, hepatitis A, visceral leishmaniasis, Lyme 
disease, Boutonneuse fever, toxoplasmosis, and certain neoplasms.
46
 
Palisading granulomas: a subtype of necrotizing granuloma in which the mononuclear 
phagocytes at the periphery have elongated or spindle-shaped nuclei that are palisaded and 
arranged roughly parallel to each other and roughly perpendicular to the edge of the central 
necrotic zone. They are characteristic for granuloma annulare but can also be found in 
rheumatoid and post-surgical necrobiotic nodules, Churg-Strauss disease, FB reactions, 
cutaneous T-cell lymphoma, Wegener’s granulomatosis or certain infectious diseases.47 
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1.4 What should be targeted in the study of granulomas?  
IHC markers relevant for the study of (NOD2-related) granulomatous inflammatory disorders 
will be discussed here. HLA-DR is a marker for antigen presenting cells
6
 and CD68 is a 
marker for the MML
7
. In chronic inflammation the MML is aided by different types of 
lymphocytes that can form different subsets that influence each other, the MML and PMN 
cells. B-lymphocytes can be distinguished from T-lymphocytes morphologically by their 
striped nucleus and slightly more abundant cytoplasm, but IHC is useful to visualize their 
overall distribution. CD20 is a maturity marker for B-lymphocytes
48, 49
, which are usually not 
associated with granulomas but evenly distributed throughout the investigated tissue, except 
for immune complex granulomas where antibodies are believed to initiate the granulomatous 
response. T-lymphocytes do not produce antibodies and can be divided in different functional 
subsets. CD8 is a marker for cytotoxic T-lymphocytes that can induce apoptosis of other cells 
via the external apoptosis pathway.
50
 CD4 is a marker for helper T-cells, which are the major 
source of lymphocytic subsets and their plasticity.
51
 Activated macrophages and activated T 
cells with the helper phenotype were previously described in adults with sarcoidosis
52, 53
 as 
well as in patients with CD.
54
 Of particular interest for the granulomatous response, as 
discussed further in part 4 of this introduction, is the IL23R that is necessary for the 
maintenance of the recently discovered Th17 subset involved in auto-immunity and 
granulomatous diseases such as TBC and sarcoidosis.
55
 Different lymphocytic subsets make 
use of distinct cytokine panels for functional immune signalling. We are the first to IHC stain 
a panel of Th1 cytokines IL1β, TNFα, IFNγ, Th2 cytokine IL10, Th17 cytokine IL17 and the 
instructive cytokines for Th17 formation IL6 and TGFβ in BS. IHC detection of Th1 
cytokines in CD and of Th17 cytokines in sarcoidosis was already reported by other authors. 
Others have reported a more important role for Th1 lymphocytes in granulomatous 
inflammation in AS
52, 53, 56-60
 and CD
61- 64
.
 
Because NOD2 contains domains involved in 
cell death, we have also selected Fas and FasL as markers for external apoptosis pathway 
stimulation
65
, anti-apoptotic B-cell lymphoma (Bcl) 2 protein as internal cellular stress 
marker
66
 and activated Caspase (aC) 3 as the effector of conventional apoptosis.
67
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Leukocyte markers on the cell surface such as CD4, CD8, CD19, CD43, CD68, HLA-DR and 
IL23R require a different technical approach and pathological interpretation than stored and 
secreted signalling molecules such as IFNγ, insulin like growth factor binding protein 3 
(IGFBP3), IL1α, IL1β, IL6, IL8, IL10, IL12/23 subunit p40, IL16, IL17, IL23 subunit p19, 
placental growth factor (PlGF), TGFβ and TNFα. If a leukocyte marker is specific for a 
certain cell type, the positive cells per high power field can be counted under the microscope. 
Only semi-quantitative scoring of secreted targets such as cytokines is possible since there are 
produced by many different cell types and secreted in the inflammatory infiltrate. Other 
targets such as aC3, Bcl2, Fas and FasL involved in cell death and nuclear factor κ-light-
chain-enhancer of activated B cells (NF-κB), receptor-interacting serine/threonine-protein 
kinase (RIPK) 2 regulating pro-inflammatory Th1 gene transcription, retinoic acid receptor 
(RAR)-related orphan receptor (ROR) γT regulating Th17 differentiation68 and S100A12 
released from MML and PMN cells during activation of the innate immune system
69
 were 
selected to investigate the relation between NOD2 and cell death, Th1-Th17 balance and a 
candidate non-invasive marker for auto-inflammation found in circulation and faeces. We 
have thoroughly investigated the relation between NOD2 and cell death in granulomas, but 
were hampered in learning more about Th1-Th17 balance because we could not find a decent 
commercial antibody for RORγT or IL23 subunits p19 and p40 essential for survival and 
maintenance of Th17 in molecular competition with IL12 (shared subunit p40). We will 
define our own diagnostic and prognostic features of auto-inflammation next to S100A12.  
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2. PATHOGEN SENSORS AND INNATE IMMUNITY: FOCUS ON NOD2 
Pattern recognition receptors are a family of germline-encoded proteins present in innate 
immune cells, especially in macrophages and dendritic cells, and to a lesser extent in reactive 
epithelial cells, endothelial cells, and fibroblasts that recognize pathogen- and damage- 
associated molecular patterns in a specific evolutionarily conserved way.
70
 Transmembrane 
proteins such as Toll-like receptors sensing the extracellular space and intracellular proteins 
such as Nod-like receptors (NLRs) sensing intracellular cues both induce inflammation 
through formation of various multimeric protein complexes such as the inflammasome, a 
multiprotein oligomer containing apoptosis-associated speck-like protein containing a 
caspase activation and recruitment domain (CARD), NLRs and caspases.
71
 Caspase 1 is 
important for the initiation of the inflammatory response through cleavage of pro-IL1 into 
IL1α and IL1β. When (one of) the NLR(s) in the inflammasome is NOD1 or NOD2, it is 
called the nodosome.
72
 In addition other caspases associated with cell death can be recruited 
to the complex. The intracellular localization of NLRs reflects their specificity for molecular 
patterns associated with intracellular danger signals such as intracellular pathogens, foreign 
bodies or sequestering autophagy products. NOD2 is crucially involved in the recognition of 
breakdown products of the autophagosomes and the feedback regulation of the autophagy 
pathway important for cellular recycling and survival.
73
 Multiple studies have shown that 
NOD2 acts as a non-redundant recognition molecule of Mycobacterium, a virulent 
intracellular pathogen resistant to many therapies.
74
 Therefore it is not surprising that the 
classic granulomatous response, traditionally seen as the result of frustrated phagocytosis, is 
associated with TBC and dependent on NOD2 signalling. The NOD2 gene encodes a 
cytoplasmic protein comprised of two N-terminal CARDs, one central NOD/NACHT 
domain, and C-terminal leucine-rich repeats (LRRs).
75
 It is expressed constitutively in innate 
immune cells including monocytes, macrophages, neutrophils and dendritic cells, as well as 
in Paneth cells in the small intestine, which are of epithelial origin.
75, 76
 NOD2 serves as a 
pathogen sensor via its LRR domain through recognition of muramyl dipeptide, a 
peptidoglycan motif present in the cell wall of gram-positive and gram-negative bacteria.
77, 78 
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After ligand binding, the NOD2 proteins undergo NACHT domain-mediated self-
oligomerisation, leading to the activation of the N-terminal CARDs and binding to the pivotal 
downstream receptor-interacting serine/threonine kinase through CARD-CARD interaction. 
This mediates NF-κB activation and subsequent induction of genes encoding pro-
inflammatory cytokines and chemokines initiating local innate immune responses.
79
 Whereas 
the genetic contribution of NOD2 variants to the pathogenesis of BS and (p)CD has been 
confirmed in recent years
81
, the relation between different NOD2 variants and the molecular 
immunopathology as well as the clinical expression of BS and (p)CD remains to be 
elucidated.
81
 A role for NOD2 in autophagy has recently been reported as well.
82
 In 
accordance with the increased basal NF-κB response to muramyl dipeptide (MDP) observed 
in HEK293T cells cotransfected with constructs with Blau mutations and a NF-κB reporter 
plasmid in vitro,
83, 84
 it is hypothesized that gain-of-function mutations affect the activating 
NOD/NACHT domain of NOD2 and cause granulomatous auto-inflammation in BS, while 
loss-of-function single nucleotide polymorphisms (SNPs) affect the pathogen-sensing LRRs 
of NOD2, disable innate immune cells and render the patient susceptible to infections in 
(p)CD. Although CD is believed to be a multifactorial diseases caused by disruptions in the 
balance between innate immunity and intestinal flora, there is growing evidence to support 
the macrophage ID theory of CD.
85
 It remains enigmatic why CD principally occurs in the 
gut, while the macrophage phenotype is systemic. As suggested by the bacterial load–
dependent clearance defect, the anatomical selectivity of disease may reflect the uniquely 
high bacterial load in the intestinal lumen, which is not found at any other interface. The 
bacterial content in the gastrointestinal tract is huge when compared with other locations, 
such as the skin or the respiratory, urinary, or genital tracts. In fact, the ID might explain the 
apparently high rate of appendicitis in patients with CD.
86
 To further bridge innate immunity 
and auto-inflammation these questions need to be addressed by investigating how NOD2 
variants affect downstream pathways such as antigen presentation, mononuclear maturation, 
pro-inflammatory gene transcription, caspase activation and autophagy induction resulting in 
distinct disease manifestation and granuloma phenotype in NOD2-associated diseases.
87
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3. NOD2-RELATED GRANULOMATOUS INFLAMMATORY DISEASES  
In recent years, the NLR family has been found to play a pivotal role in an expanding number 
of monogenic and polygenic human inflammatory diseases. At the molecular level, NLR 
proteins function as pattern recognition receptors for intracellular bacterial constituents and as 
sensors of cellular metabolic stress; they are implicated in inflammation and apoptosis 
pathways.
93, 94
 NOD2 a.k.a. CARD15 is a NLR family member stimulating pro-inflammatory 
signaling and cytokine networks as a consequence of NF-κB activation.95 Mutations in NOD2 
are associated with a number of human inflammatory disorders, including (p)CD and BS. 
Different SNPs affecting the C-terminal LRRs of NOD2 were shown to be associated with 
susceptibility to (p)CD, a polygenic, chronic inflammatory bowel disease (IBD) characterized 
by granulomatous inflammation, primarily localized to the terminal ileum (Figure I.7).
96, 97
  
 
 
 
Figure I.7. The NOD2 gene: most BS mutations affect the central activating NOD/NACHT domain, 
while most CD-associated SNPs are located to the C-terminal pathogen-sensing LRR domains. 
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3.1 Blau Syndrome, a monogenic orphan disease 
Pediatric sarcoidosis (PS) is a children’s disease that is characterized by non-caseating 
epithelioid granulomas without infectious etiology and comprises different entities including 
Blau syndrome (BS), infantile onset panniculitis with systemic granulomatosis (IOPSG), 
adult type pediatric sarcoidosis (ATPS) and unclassified PS (UPS). BS is a hereditary auto-
inflammatory disease that is typically characterized by a clinical triad of granulomatous 
uveitis, arthritis and dermatitis but that can affect almost any part of the body.
91, 92
 (Figures 
I.8 and I.9) It is caused by gain-of-function mutations in the NOD/NACHT domain of the 
nucleotide oligomerisation domain 2 (NOD2) protein. This clinical entity comprises BS, the 
autosomal dominant familial form, and early onset sarcoidosis (EOS), the sporadic form.
83, 89, 
98 
For other idiopathic systemic granulomatous diseases in young children no genetic or 
infectious causes have been identified yet. One of these is IOPSG, a distinct clinico-
pathological entity that was described recently and was not found to be associated with 
NOD2 mutations.
99
 Also for PS starting at a later age and clinically resembling the adult 
sarcoidosis (AS), no genetic cause has been revealed at present.
100 
Finally UPS is the most 
enigmatic collection of granulomatous diseases in childrenwithout NOD2 mutations to date. 
 
 
Figure I.8. Comparative Pie Chart: Cumulative clinical manifestations in 75 (NOD2+ and NOD2-) PS.  
Summarized clinical PS spectrum: NOD2+ PS = PGA = BS + EOS and NOD2- PS = IOPSG + ATPS + UPS. 
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BLAU CLINICAL TRIAD 
 
Figure I.9. BS clinical triad of granulomatous A) Uveitis B) Arthritis and C) Dermatitis. 
38 
 
3.2 Crohn’s disease, a multifactorial inflammatory bowel disease 
CD is an idiopathic inflammatory bowel disease in which granulomatous inflammation of the 
intestine is one of the diagnostic features. Patients with CD may also exhibit extra-intestinal 
features including rash, arthritis and inflammatory eye disease.
101
 Presence of mucosal and 
submucosal granulomatous inflammation is one of the pathological features that can help to 
distinguish between CD and ulcerative colitis. Among other factors, the single nucleotide 
polymorphisms (SNPs) R702W and G908R and the frame-shift mutation L1007fsinsC-/C in 
the leucine-rich repeat domain of the NOD2 gene have been shown to be associated with CD 
in 30% of patients.
102, 103
 CD-associated SNP’s in NOD2 are believed to render the patient 
more susceptible to chronic inflammation of the bowel due to a loss-of-function resulting in 
lethargic macrophages and opportunistic infections.
84
 NOD2 SNPs are associated with the 
stenotic subtype of CD, probably due to sclerosis of the intestine (Figure I.10).
104
 SNPs in 
autophagy pathway genes ATG1, ATG16L1 and IRGM have also been  linked to CD.
105
 
Other CD-associated SNPs were found in the anti-inflammatory IL10 gene
106
 and IL23R
107 
and IL12B
108
 genes involved in Th17 differentiation. Products of these genes are crucial for 
MML function. Anal CD has a worse prognosis, possibly due to a higher bacterial load.
109
 A 
probable explanation for CD is a disrupted balance between innate immunity and gut flora. 
Figure I.10. Stenotic subtype of (p)CD associated with NOD2 SNPs A) isolated small epithelioid 
granuloma with only small MGCs and without a lymphocytic corona B) increased eosinophils and 
sclerosis in the intestine, resulting in stenosis of the gut, immobility and more severe disease. (x400) 
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3.3 NOD2 variants in adult sarcoidosis  
Classic AS is an idiopathic multisystemic disease characterized by sclerosing granulomas in 
the lung and other organs.
110
 The CD-associated NOD2 variant R702W has recently been 
associated with severe pulmonary adult sarcoidosis (AS-P) as well.
111
 Next to the CD-
associated SNP R702W another NOD2 variant, lung function-associated SNP R587R, was 
associated with severe AS-P.
 110
 AS is an exclusion diagnosis of idiopathic multisystemic 
granulomatosis that typically affects the lung and shows a lymphatic distribution pattern. 
Extrapulmonary adult sarcoidosis (AS-EP) is atypical but can be observed as well: 
extrapulmonary renal adult sarcoidosis (AS-EP-R) is a well known example.
112
 Sarcoid 
granulomas typically consist of epithelioid cells surrounded by concentric sclerosis and 
usually contain (Langhans type) MGCs that can contain remarkable histopathologic findings 
such as asteroid and Schaumann bodies historically linked to sarcoidosis (Figure I.11), but 
considered less specific for it now. The origin of these bodies remains enigmatic. Asteroid 
bodies are believed to be elements of the cytoskeleton of MGCs. The biochemical 
composition of Schaumann bodies has been determined by Reid and Andersen as mainly 
calcium oxalate.
39
 Hypercalcemia has been associated with renal sarcoidosis and other 
types.
113
 Granuloma formation relates to failure of innate immunity that can result from Ca
2+
 
metabolism impairments due to vitamin D excess. At the tissular level, calcification of 
unknown substrates might produce Schaumann bodies. 
Figure I.11. MGCs in sarcoid granulomas can show A) asteroid bodies or B) Schaumann bodies(x400) 
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4. GRANULOMATOUS INFLAMMATORY DISEASES WITH WILD TYPE 
NOD2  
The relevance of the BS as a model for granulomatous auto-inflammation to investigate 
granuloma pathology of NOD2-associated idiopathic granulomatous diseases such as pCD 
and AS was already discussed above. Here we will use a similar approach to compare PS, CD 
ans AS granuloma morphology with rare immune-genetic knock-out models of specific 
MML-assisting cell types. Acute inflammation by neutrophils and monocytes (immediate 
innate immune response) can lead to chronic inflammation with monocytes and lymphocytes 
(propagate adaptive immune response). First chronic granulomatous disease (CGD), a 
primary neutrophil immune deficiency, is a naturally occurring knock-out model selective for 
neutrophils and associated with granulomas compensating for the innate immune disorder and 
acute response. This mutation-proven CGD patient provides good arguments regarding the 
hypo-inflammatory granuloma phenotype associated with innate immune deficiency 
(suspected to affect macrophage functions in pCD) and futile neutrophil recruitment 
associated with Th17. Second cartilage hair hypoplasia (CCH), a primary lymphocyte 
immune deficiency, is a naturally occurring knock-out model selective for lymphocytes and 
can be associated with granulomas. CHH is a good model to study what Chensue defined as 
persisting high turnover innate granulomas, a type of hyper-inflammatory granulomas. In the 
setting of CHH this phenotype is observed during adaptive immune deficiency inducing 
unchecked granulomatous inflammation due to abolished regulation by functional 
lymphocytic subsets. In contrast to granulomatous auto-inflammation in BS with 
inappropriate activity of NOD2 and downstream signalling cascades, both CGD and CHH 
patients carry wild type NOD2 and are hence unaffected in this pathway. As mentioned 
earlier, several children with idiopathic granulomatous inflammatory disease and wild type 
NOD2 were considered for NOD2 genotyping to diagnose BS. The BCS inclusion criteria 
mention the necessity of mutation-proven BS in candidate patients.  We studied CGD and 
CHH together with BS, pCD and AS patients, but did not include the results in this thesis. 
41 
 
4.1 Chronic Granulomatous Disease, a primary neutrophil immune deficiency 
CGD is a primary immunodeficiency characterized by defects in superoxide (O2-) production 
by neutrophils resulting from mutations in one of the four NADPH oxidase components and 
predisposing to opportunistic infection of organs in direct contact with the environment such 
as gut and lung. The CGD phenotype rather constitutes a hypergranulomatous compensation 
of phagocyte ID than Rieber’s hyperinflammation.114 In (p)CD the balance between the innate 
immune cells protecting the intestinal epithelial barrier and gut microflora is believed to be 
disturbed. SNPs in genes essential to macrophage function have been associated with (p)CD 
and therefore both ‘macrophage lethargy’ and ‘altered intestinal flora’ are thought to 
contribute to (p)CD. In contrast, typical opportunistic infections by fungi indicate a much 
more severe ID in CGD. This is supported by the observation of functional (but lethargic) 
macrophages in (p)CD that are still able to form (hypo-inflammatory) granulomas versus idle 
neutrophils surrounding fungal hyphae in CGD that cannot even die properly or degranulate 
creating pus (Figure I.12). Besides the O2- defect, neutrophils from CGD patients show 
resistance to cell death, a phenomenon connected to chronic inflammation and predisposition 
to autoimmunity.
114, 115
 CGD can be a naturally occuring neutrophil function knock-out 
model to study the compensatory mechanisms of the MML in immune granulomas. 
 
Figure I.12. Lung with opportunistic aspergillus infection in CGD A) H&E shows a bronchocentric 
granulomatosis with idle neutrophils in the centre cyrcled by epithelioid macrophages and MGCs 
(x200) B) Grocott’s methenamine silver stains fungal hyphae with aspergillus morphology (x400). 
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4.2 Cartilage-Hair Hypoplasia, a primary lymphocyte immune deficiency 
The cartilage-hair hypoplasia / anauxetic dysplasia (CHH-AD) spectrum disorders are 
characterized by severe disproportionate (short-limb) short stature which is usually 
recognized in the newborn, and occasionally prenatally because of the short extremities. It 
was first recognized in the Old Order Amish population.
116
 This condition shows an 
exceptionally high prevalence in Finland, but sporadic cases occur worldwide. Other findings 
include joint hypermobility and often fine silky hair, ID, anemia, impaired spermatogenesis, 
gastrointestinal dysfunction, and increased risk for malignancy. An increased risk of cancer 
has also been reported.
117-118
 The clinical manifestations of the CHH-AD spectrum disorders 
are variable, even within the same family. Diagnosis of the CHH-AD spectrum disorders is 
based on clinical findings, characteristic radiographic findings, and in some cases, evidence 
of immune dysfunction, macrocytic anemia, and/or gastrointestinal problems. The RNA 
component of mitochondrial RNA processing endoribonuclease (RMRP) gene is the only in 
which mutations cause the CHH-AD spectrum disorders.
119
 Molecular genetic testing is 
available to confirm the diagnosis. Although a strong genotype-phenotype correlation has 
been found by means of in vitro testing of different mutations,
120
 patients with the same 
genotype can show very variable degrees of immunodeficiency.
121
 CHH is a rare autosomal 
recessive disorder and some patients also have defects in cell-mediated immunity and 
antibody production. 
122, 123
 An increase in mortality associated with defective immunity has 
been reported.
124
 Other features of CHH include hypoplastic anemia.
123
  Granulomatous 
inflammation has been described in patients with various forms of primary ID but had not 
been reported in patients with CHH before. In collaboration with Hôpital Necker Enfants 
Malades in Paris, we sought to describe granulomatous inflammation as a novel feature in 
patients with CHH, assess associated ID, and evaluate treatment options. Although several 
groups have reported successful immune reconstitution after allogeneic hematopoietic stem 
cell transplantation (HSCT),
125-128
 this therapy does not change the course of skeletal 
dysplasia. Both the effect of HSCT on the increased risk of malignancy and the risks an 
benefits of anti-TNFα therapy remains to be elucidated. 
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4.3 Infantile Onset Panniculitis with Systemic Granulomatosis, a new disease
99 
Wouters et al reported four infants that had a previously unrecognized syndrome consisting of 
febrile lobular panniculitis associated with arthritis, uveitis and systemic granulomatous 
inflammation, recruited through the former International Registry of Pediatric Granulomatous 
Arthritis (PGA).
99
 In contrast to BS setting on during todling, IOPSG sets on right after birth 
or during infancy. Neither CARD15 nor cold-induced auto-inflammatory syndrome (CIAS) 1 
mutations were found. Disease course was progressive despite immunosuppressive therapy. 4 
IOPSG patients showed a severe phenotype including visual impairment in 2 cases and 
widespread granulomatous inflammation with fatal outcome due to diffuse lung involvement 
in one patient. Partial response to anti-TNFα monoclonal antibody in 3 patients was of note.  
 
4.4 Adult-type pediatric sarcoidosis 
In addition to IOPSG there are PS patients that resemble the adult type (ATPS) clinically 
because of pulmonary involvement, classic sclerosing granuloma aggregates and onset during 
adolescence.This term is purely descriptive to refer to a minority of PS that exhibit the 
stereotypical features of classic AS, namely: pulmonary involvement with a lymphatic 
distribution pattern and multisystemic granulomatosis with the formation of sclerosing 
granuloma aggregates. Although concentric sclerosis is a characteristic histopathological 
feature of granulomas in AS, it has not been clearly associated with any of the known types 
of PS to this very date. Besides biopsies from 3 distinct PS subtypes BS, IOPSG and ATPS, 
other children with unclassified PS were referred to us or retrospectively selected from the 
pathological archive of the University Hospitals of Leuven, Belgium. 
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5. TH17 OR THE FIRST MAJOR REVISION OF THE TH1-TH2 
HYPOTHESIS 
In the Th1-Th2 hypothesis the granulomatous response was polarized by the involvement of 
two opposing CD4+ Helper T-lymphocytic subsets: Th1 (mycobacterium tuberculosis) and 
Th2 (schistosoma mansoni).
16, 17
 Because of the abundant Th1 cytokine production by the 
localized aggregate of MML cells, which are part of the innate immune system themselves, it 
is more likely that the non-specific T cells recruited to the granulomatoid inflammatory 
infiltrate will be Th1 polarized by cytokines such as IFNγ and IL6. Therefore, it is most likely 
that granulomatous inflammation is initially Th1 polarized in terms of the Th1-Th2 
hypothesis, and that the additional Th2 component that is observed sometimes (for example 
in schistosoma mansoni infection) can be superimposed later in disease-specific conditions 
that lead to the recruitment of non-MML cells such as eosinophil PMN cells during the 
transition to a complex granuloma. The cytokines secreted by the eosinophilic granulocyte 
(IL-1, IL-2, IL-4, IL-5, IL-6, IL-8, IL-13 and TNF-α) partially resemble a Th2 cytokine 
signature  that can be falsely interpreted as Th2 polarization of the entire inflammatory 
infiltrate. However, the majority of leukocytes in every phase of granulomatous inflammation 
are activated MML cells, and their cytokines will induce and maintain Th1 polarization 
throughout the process. In other words, the balance of Th1-Th2 polarizing cytokines leans in 
favor of the Th1 axis throughout the entire process of granulomatous inflammation, and the 
additional Th2-like counterweight in disease-specific conditions is too small to tip the 
balance and persist. The delayed type hypersensitivity reaction associated with 
mycobacterium tuberculosis infection is considered to be Th1-mediated in the light of the 
Th1-Th2 hypothesis. Over the past 9 years, there has been a remarkable evolution in thinking, 
leading us to revise our opinions about Th1 and to develop a new model to explain the 
regulation of cell-mediated tissue damage, which underlies pathology in many auto-immune 
conditions and microbial infections. This new model is called the Th17 hypothesis and it is 
the first significant revision of the Th1-Th2 hypothesis since it was formulated in 1986. 
25
 
The finetuned balance between Th1, Th2, Th17 and Treg needs further investigation. 
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In 2003, Cua et al reported in Nature that IL23 rather than IL12 is the critical cytokine for 
auto-immune inflammation of the brain.
55
 This was concluded from the observation that Th1 
cells were not required for induction of experimental auto-immune encephalomyelitis in 
mice, as had been thought, but an IL23-dependent set of T cells that was later identified as the 
Th17 cell subset. IL23 signalling is necessary for survival and maintenance, but not 
differentiation, of the Th17 subset. IL23R is only expressed after activation of naïve T cells. 
The IL12/IL23 balance is regulated by competition for the same subunit p40 and determines 
the Th1/Th17 balance in the infiltrate. IL23 consists of a p19 and the shared p40 subunit. The 
Th1 cytokine IL12 is made up of a p70 structure, composed of a p35 and the shared p40 
subunit, and is an important regulatory cytokine that has a pivotal function in the initiation 
and regulation of cellular immune responses.
25
 It can regulate the differentiation of naive T 
cells, which are crucial in determining resistance and the type of response that will be elicited 
against a particular pathogen.
129
  IL-12 is produced by macrophages, monocytes, dendritic 
and B cells in response to bacterial products and intracellular parasites. IL12 is also primarily 
responsible for the subsequent production of interferon-gamma (IFN-γ) and tumor necrosis 
factor-alpha (TNF-α) from NK cells and T helper cells. IL-12-induced IFN-γ secretion 
enhances phagocytosis, production of nitric oxide, and oxidative burst, resulting in increased 
destruction of pathogens.
130 
 
Figure I.13. IL6 and TGFβ instruct Th17 formation from IL23R+ Tm primed by IL23. TGFβ needs to be 
present for Th17 differentiation in combination with IL6, autostimulation in combination with IL21 
and promotion with or without IL6. All 4 pathways involve different transcription factors (TF).
131 
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RORα and RORγT are the essential transcription factors for Th17 differentiation. However, 
the recruitment of other transcription factors to the complex enables tight regulation. IFN 
regulatory factor (IRF) 4 is involved in the balance of Foxp3, RORα and RORγT during Th17 
formation.
131
 Remarkebly, Foxp3 can inhibit Runx1 and RORγT to promote regulatory T 
cells (Treg).
 131
 (Figure I.13). Hetero- and homodimers of IL17A and IL17F play a role in the 
recruitment of neutrophilic PMN cells and production of acute phase response proteins, the 
antimicrobial response against intra- and extra-cellular bacteria and fungi and upregulation of 
matrix metalloproteases 1, 3, 9, 13 that contribute to tissue damage.
131
 In addition to IL17, 
Th17 produces IL21 and IL22.  IL21 modulates both T cell biology and B cell response by 
maintenance of Th17 through autostimulation (IRF4) on one hand and differentiation of naïve 
B cells to plasma cells (Blimp1) on the other.
131
 IL22 induces antimicrobial responses of 
epithelium, such as cytokines, chemokines, acute phase proteins and defensins, is involved in 
tissue repair after cell-mediated tissue damage and enhances epithelial-barrier function 
against bacteria.
131
 Other lineages tightly regulate Th17 differentiation. Activated memory T 
cells preserve plasticity to alter their cytokine program according to the received stimuli as an 
answer to evolution of pathogens. Other lineages such as Th1, Th2, (i)Treg and also activated 
MML cells tightly regulate Th17 differentiation. Activated memory T cells preserve plasticity 
to alter their cytokine program according to the received stimuli as an answer to evolution of 
pathogens such as mycobacterium tuberculosis. 
Inhibition of Tm differentiation is essential to keep inflammation and immunity in control 
and prevent Th17 -mediated auto-immunity and/or Th17-associated auto-inflammation 
(Figure I.14).
131
 The distinction between (auto-) immunity and (auto-) inflammation is not as 
simple as the distinction between innate and adaptive immune cells suggests. Other types of 
IL17 producing immune cells beyond helper T cell type (Th17) are adaptive immune cells 
such as cytotoxic T cells (Tc17) and innate immune cells such as natural killer T cells (NK-
T17), lymphoid tissue-induced T cells (LT-i17), γδ T cells (γδ-T17). Additional myeloid cell 
types such as Paneth cells, the MML and neutrophils have been postulated to be able to 
produce IL17 as well. IL17 was cloned in 1995 as a T cell cytokine exerting inflammatory 
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effects on epithelium, endothelium and fibroblasts. Now we know the IL17R is a multimeric 
and ubiquitously expressed cytokine receptor, specifically involved in maturation of CD34+ 
haematopoietic precursors into neutrophils and induction of mononuclear maturation of 
MML into epithelioid macrophages and multinucleated giant cells. This brings us to one of 
the subjects of this manuscript, namely the role of IL17 in granulomatous inflammation. IL-
17A gene-knockout (KO) mice fail to develop mature granulomas in the Mycobacterium 
bovis bacille Calmette-Guérin (BCG)-infected lung.
132
 Also sarcoidosis is now considered to 
be a Th17 mediated multi-systemic disorder: both IL17+IFNγ+ and IL17+IL4+ memory T 
cells were found in the circulation and BAL, indicating that Th17 cells are involved in 
granuloma induction or maintenance in sarcoidosis.
133
 Futhermore, Th17 cells have been 
associated with auto-immune diseases such as rheumatoid arthritis, inflammatory bowel 
disease, multiple sclerosis, auto-immune uveitis and allergic lung disease. All these factors 
combined make it relevant to consider these new scientific developments during the selection 
of morphological and immunohistochemical parameters to investigate granulomas from a 
new point of view, namely the naturally occurring granulomatous auto-inflammation 
observed in BS patients. It has to be confirmed whether a typical auto-immune disease such 
as BS is associated with Th17 or not and to which extent NOD2 variants contribute to 
granulomatous inflammatory disease pathogenesis and granuloma cytokine profile.  
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Figure I.14. Th17 initiates regulatory mechanisms. (adapted from Strober et al.)
131
 Th17 formation 
depends on TGFβ and IL6 signalling. Treg promote Th17 formation and inhibit Th1 polarization 
through TGFβ production. Th1 associated with IFNγ and IL6, and Th17 associated with IL17 and IL22 
are in competition for a shared IL12/IL23 subunit which is crucial in Th1/Th17 balance. 
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GENERAL AIM AND OBJECTIVES      
When Prof. em. Dr. Valeer Desmet and I examined granuloma morphology of the first BS 
patients, we were immediately amazed by the granuloma phenotype they exhibited: 
polycyclic granuloma architecture with dense lymphocytic coronas and lymphocyte 
emperipolesis in MGCs (LEMGC) associated with fibrinoid necrosis and intragranulomatous 
fibrosis. ‘In my 50year long career as a liver pathologist I have never seen this extra-ordinary 
type of granulomatous inflammation…’ he noted. His immediate and honest reaction 
convinced me that the extra-ordinary clinical phenotype recognized by Dr. Edward Blau
88
, 
the identification of rare BS mutations in the NOD2 gene around the millennium
89, 90 
and the 
peculiar pathological granuloma phenotype at hand were closely related to each other.  
The Genetic Revolution enabled identification of unknown pathogenic mutations in rare 
orphan diseases for the first time in human history and this resulted in the creation of 
mutation databases such as Infevers for auto-inflammatory syndromes in 2004.
91
 In order to 
collect clinical and demographical information concerning different auto-inflammatory 
syndromes, international patient registries such as the PGA Registry in 2006 were set 
up.
92
Although few case reports of individual BS patients were already published, they did not 
pay much attention to granuloma pathology in particular. Our department is the first to 
describe granulomatous auto-inflammation in multiple organs of several BS patients 
pathologically. The description of the distinct BS granuloma phenotype with LEMGC and the 
recently discovered interaction between NOD2 and the autophagy pathway made us wonder: 
is this the microscopical phenotype of inappropriate NOD2-autophagy signalling? The initial 
communication attracted further interest, means and candidate patients for our international 
research propagated from the PGA Registry, the pathological archive and new referrals. 
Supervized by Prof. Dr. Gert De Hertogh and Prof. Dr. Erik Verbeken I assessed a 
standardized set of morphological and IHC features of granulomas in respectively pCD and 
AS patients selected retrospectively.  
The reason NOD2-related diseases are of the utmost clinical relevance is that mutations in 
this gene are associated with both monogenic and polygenic human inflammatory conditions 
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in which several different immune-pathogenic mechanisms may be involved. Efforts to 
investigate downstream effects of NOD2 mutations have been hampered by difficulties in 
creating a murine phenotype of the disease, which may relate to the important role of species-
specific tissue-specific factors in disease pathogenesis.
134, 135
 In this manuscript we focus on 
human diseases and samples to investigate the role of the NOD2 pathway in inflammation. A 
better understanding of NOD2 variants and disease pathogenesis is of direct relevance as well 
for the development of targeted immunotherapy for these rare disorders. To elucidate the 
granuloma enigma we aim to compare genetic background, histopathology, cellular 
composition and cytokine pathways involved in granuloma formation and clinical features of 
children with PS, pCD and ID and adults with AS. The general aims of this manuscript are 
the following: 
 
Aim1: Define a system for granuloma staging based on personal observations & literature 
Aim2: Determine NOD2 gene variants for children with PS, pCD, ID and adults with AS 
a. Whole NOD2 gene sequencing of PS patients in cooperation with Casey Eye Institute 
b. Genotyping of pCD/AS patients for known disease associated SNPs in NOD2 
c. Mutation screening of ID patients in cooperation with Hôpital Necker Enfants Malades 
Aim3: Histopathological characterization of granulomas in NOD2
+
 and NOD2
-
 patients 
a. Morphology of granulomas (staging) and changes in the surrounding tissue 
b. Morphological correlates of cellular stress and death 
c. Screen the selected patients for a novel histopatholigcal feature: the granuloma-in-follicle 
Aim4: Cellular characterization of granulomas in children in NOD2
+
 and NOD2
-
 patients 
a. Identification of different types of leukocytes using IHC 
b. Involvement of different lymphocytic subsets and their specific cytokines 
c. Characterization of different cellular stress and death pathways using IHC 
Aim5: Clinical and pharmacological characterization of NOD2
+
 and NOD2
-
 patients 
a. Review the clinical and pharmacological data from the selected patients 
b. Construct a database for the international multicentric Blau Cohort Study (BCS) 
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In the provisional doctoral plan we envisaged (antibody-guided) laser capture microdissection 
of granulomas as well. We did not succeed in collecting sufficient snap-frozen biopsy 
material from foreign centers because of stringent (ethical) regulations. In vitro MGC and 
granuloma formation studies can be the subject of future research. Furthermore, the genetic 
cause of ID could only be determined in 2 out of 12 investigated idiopathic pediatric 
granulomatous diseases. In collaboration with Hôpital Necker Enfants Malades in Paris, 
France we applied our IHC granuloma-set to a selection of paediatric panniculitis biopsies 
with and without granulomas in an attempt to shed a light on IOPSG, a separate clinical 
entity.
99
 Only mutation proven PS patients will be discussed here to reduce the complexity of 
the discussion. I would like to conclude with the general aim of this research which is to gain 
insight in granuloma pathology using naturally occurring study model for granulomatous 
auto-inflammation (BS) and ID (CGD and CHH) to provide research data that can aid in the 
development of histopathological criteria for diagnosis and prognosis of granulomatous auto-
inflammation related to NOD2 and provide possible therapeutical targets. We will do this by 
comparing granulomas between PS, pCD and AS with and without NOD2 variants and 
mutation proven knock-out models: primary neutrophil (CGD) and lymphocyte (CHH) ID. In 
addition to final doctoral plan we studied emperipolesis in Rosai-Dorfman disease (RDD).
136
 
Our findings concerning emperipolesis target specificity and outcome of host and target cells 
lie beyond the scope of this manuscript that deals with NOD2 related granuloma pathology. 
Emperipolesis is a diagnostic feature of RDD, otherwise unrelated to granulomas or NOD2. 
Based on literature data and examples from the pathological archive of our department, we 
will define the granuloma first, discuss the role of different MML cells in granuloma 
formation second, associate the different phases of granuloma formation with their 
morphological stages third and conclude with a novel histopathological feature in Section 1. 
Then we will use this methodology to describe granulomas in NOD2-related BS, pCD and 
AS in Section 2. Last but not least we will use our findings to shed a modest light on other 
enigmatic inflammatory syndromes and the outcome of organ transplantation idiopathic 
granulomatous inflammation diseases. 
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PATIENTS AND METHODOLOGY  
1. PATIENT SELECTION AND BIOPSY MATERIAL 
All 20 PS patients, comprising 11 BS, 5 IOPSG, 4 ATPS and one isolated recurrent hepatic 
sarcoidosis patient, were actively recruited through the international Blau Registry and were 
affected by biopsy-proven granulomatous inflammation. We investigated 7 NOD2+ and 16 
NOD2- pCD patients recruited from Gasthuisberg, Leuven, Belgium after retrospective 
selection of pCD patients that showed granulomas on biopsy and were tested for 3 CD-
associated NOD2 mutations (in collaboration with Prof. Dr. G. De Hertogh). We investigated 
23 AS patients with snap-frozen biopsy tissue initially selected to perform microdissection (in 
collaboration with Prof. Dr. E. Verbeken). Various other pediatric immune diseases have 
been investigated as well. They were either recruited through the international Blau Registry 
(NOD2- PS), in collaboration with Hôpital Necker Enfants Malades in Paris (RD) or the 
academic hospital Gasthuisberg Leuven (ID) after informed consent was obtained. The 
causative mutation of ID in children with granulomas secondary to ID could only be 
determined in a minority of studied cases: 1 CGD and 2 CHH patients with granulomas.  
 
2. GENOTYPING 
The genotyping of PS patients was performed as previously described.
92
 Genomic 
deoxyribonucleic acid (DNA) was extracted from peripheral blood samples collected at the 
collaborating centers. For genotyping, genomic DNA was subjected to polymerase chain 
reaction (PCR) amplification using either FastStart Taq DNA polymerase with GC-Rich 
solution (Roche Diagnostics, Mannheim, Germany) or Optimase Polymerase (Transgenomic, 
Omaha, NE), and a touchdown PCR strategy. Primers were designed to amplify regions of 
the NOD2 gene containing the known BS mutations encoding substitutions at position 334, 
known common non–disease-associated polymorphisms, and the 3 (p)CD–associated single 
nucleotide polymorphisms (SNPs). The resultant PCR products were subjected to denaturing 
high-performance liquid chromatography analysis to screen for the presence of 
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mutations/polymorphisms (WAVE; Transgenomic). Amplicons that screened positive by 
dHPLC were subsequently subjected to direct DNA re-sequencing (in both directions) to 
confirm the mutation/polymorphism. If no BS mutation was detected, the entire coding 
region of exon 4 was sequenced in both directions to identify any previously unreported 
mutations present in the sample. The genotyping of pCD and AS patients was performed as 
described previously.
137 DNA was isolated from whole venous blood and stored at −80°C. 
Patients were genotyped for the three main (p)CD-associated SNPs in NOD2 (Arg702Trp, 
Gly908Arg, and Leu1007InsC) using PCR restriction fragment length polymorphisms. DNA 
restriction fragments were separated on agarose gels and visualised by ethidium bromide.  
 
3. MORPHOLOGY 
To study granuloma morphology, 5 µm thick, haematoxylin and eosin (H&E)-stained tissue 
slides were used. For selected biopsy sites and techniques, protocols were optimized to 
improve preservation of morphology: B5 fixation for bone marrow cores and Carnoy fixation 
for endoscopic biopsies of the gastro-intestinal tract. A standardized set of morphological 
features was studied, including granuloma staging, the presence of epithelioid cells, 
(Langhans type) MGCs, polycyclic granuloma architecture, lymphocytic coronas around the 
granuloma centre, refractive inclusions in MGCs, emperipolesis of lymphocytes in MGCs, 
apoptotic MGCs, fibrinoid necrosis in the granuloma centre, caseating necrosis in the 
granuloma centre, intragranulomatous fibrosis, granulomas-in-follicle (GIF)  in centre of 
secondary lymphoid tissue, sclerosis of the surrounding tissue and the composition of the 
inflammatory infiltrate (PMN, MML and lymphocytes) in the surrounding tissue. To describe 
the morphology of cellular stress and death we investigated for the presence of pyknosis, 
karyorrhexis, hypereosinophilia, microvesicles and macrovesicles in MGCs. The term 
‘polycyclic granuloma’ was used here to describe granuloma architecture in which individual 
circular granulomas coalesce, but are neither separated by sclerosis, nor connected by 
necrosis. Excluded from the analysis were: intestinal cryptolytic granulomas since they 
usually represent a non-specific response to necrotic tissue from cryptitis and FB reactions. 
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4. IMMUNOHISTOCHEMISTRY 
For IHC tissue specimens were formalin-fixed and cut at 3 µm. To define the leukocytic 
subsets in granuloma tissue, Monoclonal antibodies directed against the following antigens 
were used: HLA-DR (Dako M0746, clone TAL.1B5) for antigen presentation and activation, 
CD68 (Dako M0814, clone KP1) for cells of the monocyte-macrophage lineage (MML), CD4 
(Dako M0716, clone MT310) and CD8 (Dako M7103, clone C8/144B) for Helper  and 
Cytotoxic T-lymphocytes respectively, CD20 (Dako M0755, clone L26) for B-lymphocytes, 
and IL-23 receptor (IL23R) (Abcam ab53656, clone IL23A/IL23) for IL-23R-expressing 
leukocytes. To define cytokine expression profiles, monoclonal antibodies were used against 
the inflammatory cytokines IL1β (Abcam ab8320, clone 11E5) associated with 
inflammasome activation; TNF-α (Peprotech 500-M26, clone K175 with Dako Linker), IFN-
γ (Abcam ab9657) and IL-6 (Abcam ab9324) associated with Th1 involvement; IL-10 
(Serotec MCA926, clone B-S10) associated with Th2 involvement; IL-17 (R&D systems 
MAB3171, clone 41802) associated with Th17 involvement and TGF-β (Novocastra NCL-
TGFB, clone TGFB17) associated with Treg involvement. To investigate cellular stress and 
cell death pathways, monoclonal antibodies were used against the internal apoptosis balance 
proteins activated Caspase (aC) 3 (Abcam ab32042, E83-77) and B-cell lymphoma 2 (Bcl) 2 
(Dako M0887, clone 124) and the external apoptosis pathway protein Fas (Santa-Cruz sc-
8009, clone B10) and a polyclonal antibody for FasL (Santa-Cruz sc-834, N20). The signal 
amplification step was applied with Dual Envision (Dako) that uses the chromogen 
DiAminoBenzidine for visualization under the light microscope. 
 
5. SEMIQUANTITATIVE SCORING OF PATHOLOGICAL FINDINGS  
The semiquantitative scores were calculated on the basis of findings in individual patients 
rather than on individual biopsies. Each slide was scored by two independent investigators 
(CEIJ and VJD for BS, CEIJ and GDH for pCD and CEIJ and EV for AS). First, the entire 
area of every available biopsy specimen was examined to determine the biopsy score. 
Dichotomous features were given a score of 0 (negative) or 1 (positive), ordinal variables 
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were given a score of 0 (negative), 1 (mild), 2 (moderate) or 3 (dense). Morphological 
features were all scored as dichotomous variables, and so was the CD4/CD8 ratio; 
specifically: when CD4≤CD8, a score of 0 was given and when CD4>CD8, a score of 1 was 
given. All other IHC staining results were scored as ordinal variables. Second, the overall 
patient score was calculated as the mean of the all biopsy scores obtained in the individual 
patient. Third, the group score (BS or pCD) was expressed as the mean score of all patient 
scores per group. For dichotomous variables the group score was represented as follows: (-) 
the feature was never observed (x=0); (+) the feature was sporadically present (0<x≤1/3); 
(++) the feature was moderately present (1/3<x≤2/3); (+++) the feature was prominently 
present (2/3<x≤1). For ordinal variables the group scores varied as followed: (-) for x=0; (+) 
for 0<x≤1; (++) for 1<x≤2; (+++) for 2<x≤3. 
 
6. BLAU COHORT STUDY (BCS) 
The BCS is a multinational uncontrolled non-randomized prospective observational study 
involving children and adults who carry a diagnosis of BS/EOS, confirmed by histology and 
mutation analysis. The aims of the BCS are to study natural history and precise clinical 
phenotypes, develop biomarkers of disease activity and advance understanding of 
downstream effect of NOD2 mutation. Study interventions include collection of longitudinal 
clinical data from 50 participants involving about 25 academic centers around the world. The 
study interventions are non-invasive and consist of comprehensive clinical evaluation, 2 plain 
films of the hands (at inception and 3 year follow-up) and ophthalmology evaluations over a 
3 year period. A blood sample and urine sample will be obtained yearly for monitoring labs, 
studies on gene expression and proteomic profile and assays with fresh peripheral blood cells, 
in search of reliable biomarkers of disease activity. There will be no collection of samples for 
DNA testing since all participants, will have the mutation analysis already performed. This 
minimal risk study involves no randomization and no use of experimental drugs or devices. 
Participants will sign a fully executed consent and assent when appropriate approved by the 
local ethical committee which will be filed and available for auditing purposes at the 
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collaborating center. Clinical information will be submitted to the coordinating center under a 
code and without identifiers. The BCS database now contains data of more than 30 BS 
patients. Furthermore BCS candidate patients worldwide are excluded if BS diagnosis cannot 
be confirmed genetically, but still included in the international registry for study. Other 
enigmatic inflammatory syndromes studied during this research are listed in Chapter 3.3. 
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CHAPTER 1.1: 
NEW INSIGHTS 
IN THE HISTOPATHOLOGY OF GRANULOMA FORMATION 
(ARTICLE UNDER REVISION)  
In the first half year of my doctoral research, an experienced pathologist (Prof. em. Dr. Valeer 
Desmet) taught me the histopathological aspects of granulomatous inflammation, by review 
of the literature and retrospective selection of cases from the pathological archive. Through 
detailed comparison between different granulomatous diseases we defined the granuloma and 
determined a staging system summarized for further IHC research (Table R1.1.1). When the 
circulating monocyte leaves the circulation and encounters the insult, it will establish itself on 
the spot and initiate mononuclear maturation into a MGC (specialized in phagocytosis) or an 
epithelioid macrophage (specialized in protein production/secretion). Foci of freshly arrived 
monocytes can already be distinguished.
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 A focal compact collection of at least 5 epithelioid 
macrophages or 2 MGCs are at least required to meet our definition of a (FB or epithelioid) 
microgranuloma. The accumulation of both epithelioid macrophages and MGCs are required 
in our definition of a mature granuloma. Macrophages produce Th1-associated cytokines 
themselves and hence the initiation and accumulation phase do not strongly depend on 
involvement of additional lymphocytic subsets. Conversely, persistence of the evoker 
requires the recruitment of other immune cell types to boost granulomatous inflammation. 
Recruitment of other immune cell types (CD4+ T-cells in particular) in a corona around the 
mature granuloma will intensify mononuclear maturation and consolidate the effect of 
granulomatous inflammation. In the terminal phase two different outcomes are possible: 
resolution and replacement of cell-mediated tissue damage by scar tissue (sclerosis) or 
superimposed histological characteristics that result from the inability to confine or destroy 
the evoker (caseating necrosis in mycobacterium tuberculosis infection or coronal 
granulomas with polycyclic architecture and LEMGC in BS). In addition to a granuloma 
staging linked to Co et al’s phases, we define granuloma-in-follicles as a novel type of 
complex granulomas found in the follicle centre of secondary lymphoid tissue of PS/CD/AS. 
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Table R1.1.1. The 4 stages of granuloma formation are associated with a distinct morphology. 
 
Morphological and IHC features associated with the different granuloma stadia: 
 
Morphologically distinct (micro-)granuloma types such as Miesscher type radial (MRG), 
coronal and sclerosing granulomas were already described in literature, but the terms micro-, 
mature and complex granuloma were added on our own account to comply with the different 
theoretical phases of granuloma formation based on common sense. A mature granuloma is 
merely a plain granuloma that consists of both epithelioid macrophages and MGCs that has 
grown beyond the size of the microgranuloma, but does not attract other immune cells to the 
site of inflammation yet. Review of different examples from the pathological archive 
suggested granuloma formation will go through each of the 4 phases summarized in Table 
R1.1.1, until the immunologic insult is removed. If it persists, the nature of the insult or the 
virulence of the pathogen gives rise to pathognomonic features in the terminal phase of 
granuloma formation. The amount of different granuloma phenotypes in the terminal phase is 
legio and therefore they are all grouped under complex granulomas. They were discussed in 
more detail in the General Introduction earlier in this manuscript. The updated morphological 
granuloma definitions and innovative staging system were presented as a literature seminar 
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on the Journal Clubs of Immunology and Anatomy & Pathology, discussed with experts from 
both fields at the start of my PhD research and summarized in a submitted review article. 
In accordance with the theoretical phases of granulomatous inflammation, we defined 5 
distinct granuloma stadia for pathological research: microgranuloma, mature granuloma, 
coronal granuloma, sclerosing granuloma and complex granuloma. Because there is a strong 
interaction between the chronic inflammatory infiltrate and its histological environment, it is 
necessary to take the histological and inflammatory features of the surrounding tissue into 
account as well. The density (discrete, moderate or dense), distribution (central, coronal, 
peripheral) and consistency of the infiltrate can provide important pathological clues and are 
described based on immune cell morphology and semi-quantitative scoring systems. Also the 
distribution and ratio of CD4/CD8 lymphocytes (normally 2:1) can be assessed by IHC. 
 
The microgranuloma
1
 is defined here as a focal collection of CD68/KP1 and HLA-DR 
expressing MML cells matured beyond the monocyte stadium, i.e. comprising at least 5 
epithelioid macrophages or 2 MGCs. These cut-off values are sensible for histopathological 
practice because the resolution of the microscope and the eye of the investigator are 
considered. Eventually such definitions should be supported by some studies involving 
different pathologists or researchers. Obviously, a solitary MGC cannot be called a 
granuloma and at least 5 adjacent epithelioid macrophages need to be recognized to 
acknowledge they morphologically differ from artifacts or ‘odd’ cells. The only definitive 
difference between a micro- and a mature granuloma is the lack of organization in the 
microgranuloma. However, freshly arrived monocytes started to mature beyond the monocyte 
stage in response to a localized insult. The definition of the microgranuloma suggests a FB 
granuloma can already be distinguished from an epithelioid one. Microgranulomas are 
formed in the initiation phase of granuloma formation. They are associated with a discrete to 
medium infiltrate that predominantly consists of neutrophils, MML cells and T cells 
(CD4/CD8≈1). Microgranulomas do not have coronas. 
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Mature granulomas are defined here as a focal, organized collections of both mononuclear (at 
least 5) and multinucleated (at least 1) CD68/KP1 and HLA-DR expressing MML cells. 
Often centrally located MGCs are surrounded by epithelioid cells (epithelioid granuloma) or 
histiocytes and monocytes (FB granuloma). MGCs of the Langhans type suggest a low cell 
turnover and complete maturation, because they have had the longevity to reorganize their 
cytoplasmic content. In this stadium the archaic distinction between epithelioid and FB 
granulomas makes sense. MGC formation and epithelioid transition are both processes of 
cellular shape change that convey functional benefits by creating a mechanical barrier 
between the surrounding tissue and the inciting agent. MGCs are specialized in minimizing 
the contact between large particles (FBs) and the surrounding tissue by phagocytosis and 
intracellular storage. FB type mature granulomas are usually formed within 3 to 9 days after 
inoculation, depending on the inciting agent. They are characterized by a low turnover and a 
long lifespan of MML cells that often contain inclusions of the ingested irritant, usually an 
inert substance or low virulence pathogen. The small amount of replacement is mostly 
assured by proliferation of MML cells in situ.
2-4
 On the other hand, interdigitating epithelioid 
cells form a strong barrier for (intracellular) pathogens because they are forced to penetrate 
several cell membranes and pass multiple cells to escape the granuloma. Epithelioid mature 
granulomas are formed in response to a higher virulence pathogen or relatively toxic 
substance after an additional 4 to 22 days, depending on the inciting agent. They are formed 
faster during a delayed hypersensitivity (DTH) reaction to such an irritant if it has been 
encountered before. They are characterized by a high turnover and a short lifespan of MML 
cells that rarely contain inclusions of the ingested irritant. Maintenance depends more on 
recruitment of new MML cells to the granuloma, because fully matured epithelioid 
macrophages usually do not divide.
2,3, 5
 This distinction between FB and epithelioid 
granulomas is only useful if the immune system can recognize the insult and determine how 
to best defend against it. Epithelioid granulomas with only few MGCs are the best defence 
against an intracellular pathogen such as mycobacterium tuberculosis, while FB granulomas 
with only few epithelioid macrophages are ideal to digest talcum powder. In more enigmatic 
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granulomatous diseases (sarcoidosis) it seems the immune system can’t make up its mind on 
how to deal with the (unidentified) antigen and exhibits both epithelioid cells and MGCs in 
(sarcoid) granulomas. Therefore this distinction still makes sense pathologically because of 
its prognostic value: grosso modo the FB/epithelioid distinction correlates with a 
particulate/infectious etiology and a good/bad prognosis respectively. Mature granulomas are 
formed in the accumulation phase of granuloma formation. They are associated with a 
discrete central infiltrate and a moderate infiltrate in the surrounding tissue, predominantly 
consisting of MML cells and T-cells (CD4/CD8>1). By definition mature granulomas do not 
have a lymphocytic corona yet.  
 
The coronal granuloma  is defined here as a mature granuloma with a lymphocytic corona at 
least three mononuclear cells wide observed on H&E. They usually are high-turnover 
granulomas, because additional inflammatory cells have been recruited to the granuloma. The 
corona mainly consists of lymphocytes accumulating within and around the granuloma. 
Coronal granulomas are associated with a moderate central infiltrate, a dense coronal 
infiltrate and a moderate peripheral infiltrate, predominantly consisting of MML cells and T-
lymphocytes (CD4/CD8 > 1) and occasionally also PMN granulocytes. 
 
The sclerosing granuloma is defined here as a mature or coronal granuloma surrounded by 
concentric sclerosis observed on Sirius Red staining. Sclerosis is formed when the inciting 
agent is degraded and high-turnover granulomas are attenuated by anti-inflammatory signals 
to low-turnover granulomas during the resolution phase. Fibroblasts from the surrounding 
tissue replace the space formerly occupied by granulomatous inflammation. If the insult is 
entirely removed, the sclerosing granuloma will dissolve entirely and the infiltrate will 
disperse completely. Sclerosing granulomas are associated with a discrete central (and 
coronal) infiltrate and discrete peripheral infiltrate, consisting mainly of MML cells and T-
lymphocytes (CD4/CD8 > 1) and usually eosinophil PMN granulocytes. 
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Complex granulomas are defined here as coronal or sclerosing granulomas with 
superimposed histological features of cell death and hyper-activation such as pus formation, 
necrosis, apoptosis and infiltration of B-lymphocytes or PMN cells. These high-turnover 
granulomas are unable to destroy or confine the insult and therefore exhibit additional 
histological characteristics depending on the inciting agent. These features can be 
pathognomonic: persistent inflammation with pus formation (suppurative granulomas in cat 
scratch disease or Yersinia infection), necrosis (caseating granulomas in TBC), lymphocyte 
emperipolesis in multinucleated giant cells (granulomatous auto-inflammation in the Blau 
syndrome (BS)) infiltration of B cells (immune complex granulomas) or granulocytes 
(eosinophil PMN cells in schistosoma mansonii granulomas).
1
 Complex granulomas are 
associated with a dense central and or coronal infiltrate and a dense peripheral infiltrate, 
consisting mainly of MML cells and T-lymphocytes (CD4/CD8 > 1) and a broad spectrum of 
other disease or target specific immune cells as mentioned above. 
 
DISCUSSION 
 
The morphological granuloma stages suggested here can be useful for differential diagnosis. 
If the insult cannot be visualized by the pathologist, micro- and mature granulomas can be 
found at the start of any granulomatous disease without giving useful diagnostic clues. For 
example these two early stages are observed in BS patients’ granulomatous dermatitis, a site 
easily accessible for topical immunosuppressive treatment, while this disease is generally 
characterized by a distinct type of complex granulomas found in deeper organ systems. 
Micro- and mature epithelioid granulomas in the intestinal (sub-)mucosa are helpful for 
diagnosis of Crohn’s disease, but stages beyond the coronal granuloma are occasionally seen 
as well. The third stage, namely the coronal granuloma, seems to be the point of no return. 
Inoccuous micro- and mature granulomas in smouldering granulomatous inflammation can 
resolve without leaving a trace of sclerosis because they do not occupy a substantial amount 
of space. Hence the two earliest stages are associated with less loss of organ function due to 
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cell mediated damage to the parenchyma. After recruitment of additional immune cell types, 
granulomatous inflammation is stimulated and directed to exacerbate in a manner that can be 
associated with well-known features such as infectious caseous or purulent necrosis or 
recently described features such as polycyclic architecture of coronal granulomas with 
lymphocyte emperipolesis in mutation-proven granulomatous auto-inflammation in BS. If 
present, IL17 detected by IHC is not specific for a specific granuloma stage or clinical entity. 
 
In addition to the granuloma stages linked with the phases of granulomatous inflammation 
described by Co et al, we would like to mention a novel feature defined as granulomas-in-
follicles (GIF) recently introduced by Janssen et al.  Immune complex granulomas associated 
with B cell recruitment have already been described earlier, but are different from GIF 
because the latter are formed in the follicle centre of existing secondary lymphoid tissue in 
the gut, lung, lymph nodes and spleen of patients suffering from several, clinically separate, 
(idiopathic) granulomatous inflammatory diseases. GIF cannot be considered as a separate 
granuloma stage or a subtype of complex granulomas, because the epithelioid granulomas 
present in the follicle centre of the affected secondary lymphoid tissue can be as inoccuous as 
a microgranulomas or can exhibit auto-inflammatory morphology in large complex 
granulomas. Therefore GIF are more likely to be related to staging of the disease rather than 
staging of individual granulomas. GIF were recognized by CEIJ and GDH during their 
investigation of granulomas in (NOD2-related) pediatric Crohn’s disease. Next to (sub-) 
mucosal granulomas, they found GIF in the follicle centre of mucosa-associated lymphoid 
tissue in the gut and mesenteric lymph nodes in 50% of investigated pediatric Crohn’s disease 
patients. Remarkebly, they were associated with features of granulomatous auto-
inflammation i.e. lymphocyte emperipolesis in MGCs, polycyclic granuloma architecture 
with lymphocytic coronas and IL17 expression and extended disease manifestation to 
anatomical parts of the gut that are associated with a distinct bacterial flora and/or  a higher 
bacterial load (such as mouth, anus, appendix) and they often showed lymph node 
involvement. Although the availability of lymphoid tissue from pediatric sarcoidosis patients 
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was limited, because of the rarity of this disease, we did find GIF in lymph node or spleen of 
33% reported Blau Syndrome (BS) and 20% infantile onset with panniculitis and systemic 
granulomatosis patients, a new clinical entity which is the most important differential 
diagnosis from BS. We have also detected GIFs in the bronchus associated lymphoid tissue, 
mediastinal lymph nodes or spleen in 31% pulmonary adult sarcoidosis patients and in 11% 
extra-pulmonary adult sarcoidosis patients. We suspect GIF can be useful to predict lymph 
node involvement and disease expansion to organ systems beyond the site of origin (e.g. the 
ileum in Crohn’s disease, the lung in classic sclerosing sarcoidosis, clinical triad in BS,…). 
Preliminary pathological data from a retrospective selection of Crohn appendix patients 
indicate the presence of GIF can predict lymph node involvement and disease expansion, 
independent of NOD2 variants. It remains to be elucidated whether bacterial (product) 
translocation or other (genetic) factors relate to GIF. We also found GIF in primary immune 
deficient children that developed granulomas to opportunistic infections such as a 
bronchocentric aspergillosis in a chronic granulomatous disease and progressive multifocal 
leukoencephalopathie due to a JC virus in a cartilage hair hypoplasia patient. The presence of 
GIF in the affected tissue of these rare experiments of nature early in the highly morbid 
disease course indicate they can be of relevance for a broad spectrum of severe 
granulomatous diseases in children and adults, independent of genetic background or type of 
comorbidities.  
 
CONCLUSION 
 
In the initiation phase MML cells secrete IL-1 and TNF-α. Autostimulation by TNF-α 
induces the expression of cell adhesion molecules and cytokines and promotes aggregation 
and progression to the accumulation phase. IL-1 induces helper T cell costimulation, essential 
for Th0 cells to develop an immunologic response to the insult, and NK cell activation.
7
 
Mononuclear maturation sustained by (auto-)stimulation and persistence of the insult is 
associated with the production of additional cytokines such as IFNα, TGFβ, MIP1α, IL6, IL8 
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and IL12 by the MML. In the Th1-Th2 hypothesis the disturbed balance between these and 
other cytokines drives Th cells to either a Th1 fate (cell-mediated) or a Th2 fate (humoral). 
The predominant presence of Th1 cytokines in granulomatoid aggregates of MML cells 
increases the probability of Th1 polarization of Th0. Therefore we suspect granulomatous 
inflammation is initially Th1 polarized and the superimposed Th2 component in disease-
specific conditions (e.g. in schistosoma mansoni infection) tailors the immune response to the 
insult by recruitment of specific immune cell types such as eosinophil PMN cells. Cytokines 
secreted by eosinophils partially resemble a Th2 signature, but this should not be interpreted 
as Th2 polarization. Chemotaxis by a small Th2 subset in the infiltrate probably suffices for 
eosinophil PMN cell recruitment. The majority of leukocytes in every phase of 
granulomatous inflammation are activated MML cells and their cytokines strongly favor Th1 
polarization, while the additional Th2-like counterweight is too small to tip the balance and 
dominate the inflammatory infiltrate. Delayed type hypersensitivity associated with 
mycobacterium tuberculosis infection is considered to be Th1-mediated. The past 9 years 
there has been a remarkable evolution of thinking, leading us to adjust our opinion regarding 
Th1, cell-mediated tissue damage and the underlying pathology in many auto-immune 
conditions and microbial infections. This new model is called the Th17 hypothesis and it is 
the first significant revision of the Th1-Th2 hypothesis since it was formulated in 1986.
8
 
Several reports from recent years have brought evidence that Th17 helper cells and the 
Interleukin-23/Th17 lymphocyte pathway are involved in various granulomatous and 
autoimmune diseases, including ANCA-associated polyangiitis,
9, 10
 schistosmiasis,
11
 
sarcoidosis,
12
 eosinophilic granulomatosis with polyangiitis
13
 granulomatous inflammation,
14
 
and Blau syndrome and Crohn’s disease.15 Further immunologic and IHC investigation has 
to, and probably will, validate the preliminary findings and consolidate the role of these and 
new cellular partners and cytokine mediators in granulomatous disease and granuloma 
formation in the years to come.
16, 17
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CHAPTER 1.2: 
GRANULOMA-IN-FOLLICLES: A NEW OBSERVATION 
 
In addition to the granuloma stages linked with the phases of granulomatous inflammation 
described by Co et al, we describe the occurrence of a novel feature, namely granulomas-in-
follicles (GIF) we recently introduced for the first time.  Immune complex granulomas 
associated with B cell recruitment have already been described earlier, but are different from 
GIF because the latter are formed in the follicle centre of existing secondary lymphoid tissue 
in the gut, lung, lymph nodes and spleen of patients suffering from several, clinically 
separate, (idiopathic) granulomatous inflammatory diseases. GIF cannot be considered as a 
separate granuloma stage or a subtype of complex granulomas, because the epithelioid 
granulomas present in the follicle centre of the affected secondary lymphoid tissue can be as 
inoccuous as a microgranulomas or can exhibit auto-inflammatory morphology in large 
complex granulomas. We recognized GIF during investigation of granulomas in (NOD2-
related) pCD. In addition to (sub-)mucosal granulomas, we found GIF in the follicle centre of 
mucosa-associated lymphoid tissue in the gut and mesenteric lymph nodes in 48% of 
investigated pCD patients. Remarkably, they were associated with features of granulomatous 
auto-inflammation i.e. lymphocyte emperipolesis in MGCs, polycyclic granuloma 
architecture with lymphocytic coronas and IL17 expression and disease manifestations in gut 
segments that are associated with a distinct bacterial flora and/or a higher bacterial load 
(mouth, anus, appendix) and often showed lymph node involvement. Although the 
availability of lymphoid tissue from pediatric sarcoidosis patients was limited, because of the 
rarity of this disease, we did find GIFs in lymph node or spleen tissue in 33% of BS and 20% 
of IOPSG. We have also detected GIFs in the bronchus associated lymphoid tissue, 
mediastinal lymph nodes or spleen in 31% pulmonary adult sarcoidosis patients and in 11% 
extra-pulmonary adult sarcoidosis patients. It remains to be elucidated whether bacterial 
(product) translocation or other (genetic) factors relate to GIF. This novel (prognostic) feature 
needs validation in other settings of granulomatous inflammation.  
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GRANULOMA-IN-FOLLICLES IN SECONDARY LYMPHOID TISSUE OF 
PEDIATRIC CROHN’S DISEASE PATIENS 
(EXTENDED ABSTRACT) 
 
BACKGROUND: SNPs in NOD2 are a major susceptibility factor for Crohn’s disease 
(CD). (Sub-) mucosal granulomas are a diagnostic feature of CD. METHODS: To better 
describe morphological and immunhistochemical featurs of pediatric CD (pCD) 
granulomas. 17 pCD patients with granulomas were genotyped for CD-associated 
mutations or polymorphisms in NOD2 and autophagy-related genes ATG1 and 
ATG16L1. Granulomas were found in intestinal biopsies of 22 out of 83 endoscopic and 
9 out of 12 surgical procedures. Of each procedure we selected one biopsy per organ to 
study the cellular composition and cytokine profile of granulomas. We stained 43 
paraffin-embedded, formalin-fixed pCD biopsies with H&E and monoclonal antibodies 
targeting leukocyte markers (HLA-DR, CD68, CD4, CD8, CD20, IL23R) and cytokines 
(TNFα, IFNγ, IL6, IL10, IL17, TGFβ). Morphology and immunohistochemistry were 
scored semi-quantitatively. RESULTS: In addition to small isolated (sub-) mucosal 
granulomas, we found granulomas in the follicle (GIF) centre of mucosa-associated 
lymphoid tissue, visualized by CD20 staining (fig).  GIF were found in half the number 
of procedures (more often in surgical than in endoscopic) in only 7 out of 17 pCD 
patients.  Exceptional lymphocyte emperipolesis in MGCs (LEMGC) and IL-17 
expression were observed, only in granulomas of pCD with GIF. The granulomas of 
patients with GIF often had a lymphocytic corona, but polycyclic granuloma 
architecture was rare. No clear relation was seen between the presence of GIF with or 
without LEMGC and SNPs in NOD2, ATG1 or ATG16L1. CONCLUSION: We defined 
GIF as a morphological characteristic in few selected pCD patients, and demonstrate 
association with emperipolesis of lymphocytes in MGCs and IL17 expression. 
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INTRODUCTION 
 
Crohn’s disease (CD) is an idiopathic inflammatory bowel disease in which granulomatous 
inflammation of the intestine is one of the diagnostic features. Patients with CD may also 
exhibit extra-intestinal features including rash, arthritis and inflammatory eye disease.
1
 The 
presence of mucosal and submucosal granulomatous inflammation is one of the pathological 
features that can help to distinguish between CD and ulcerative colitis. Amongst other 
factors, the single nucleotide polymorphisms (SNPs) R702W and G908R and the frame-shift 
mutation L1007fsinsC-/C in the leucine-rich repeats (LRR) domain of the NOD2 gene have 
been associated with CD.
2, 3
It has been suggested that a complex interplay between genetic 
and environmental factors results in the disease phenotype.
 4
  NOD2 mutations associated 
with the Blau syndrome (BS) are believed to result in a gain-of-function and granulomatous 
auto-inflammation, while CD-associated SNP’s in NOD2 are believed to render the patient 
more susceptible to chronic inflammation of the bowel due to a loss-of-function. SNPs in 
autophagy pathway genes ATG1, ATG16L1 and IRGM were recently linked to CD as well.
5
 
Other CD-associated SNPs were found in the anti-inflammatory IL10 gene
6
 and the IL23R
7
 
and IL12B
8
 genes involved in Th17 differentiation. After detailed pathological investigation 
of BS granulomas, we wanted to use the same standardized set of immunhistochemical (IHC) 
and morphological features to describe pediatric CD (pCD) granulomas. The initial abstract 
above was based on 17 patients, later the study was expanded to 23 patients for IHC study. 
The term granuloma-in-follicle is a novel concept, although its morphological features have 
been described in the seventies.
9, 10
 Conchoid, a.k.a. Schaumann, bodies in MGCs of CD 
granulomas have been described in the seventies as well.
11 
In this study we looked for 
features typical of BS, notably polycyclic granuloma architecture with lymphocytic coronas, 
multinucleated giant cell (MGCs) death associated with lymphocyte emperipolesis and 
expression of TGFβ, IL6 and IL17 associated with Th17 involvement.  
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MATERIAL AND METHODS 
 
We determined genetic NOD2, ATG1 and ATG16L1 variants in 23 pCD patients exhibiting 
granulomas in at least one of their biopsies. All biopsies were obtained when patients were 
younger than 20 years of age. The median age at disease onset was 14 years (range 9 to 19 
years). Granulomas were found in intestinal biopsies of 30 out of 96 endoscopic and 9 out of 
12 surgical procedures. Of each procedure we selected one biopsy with granulomas per 
organ. A total amount 53 intestinal pCD biopsies with granulomas, comprising 38 endoscopic 
and 15 resected samples was selected, including oropharynx(1), oesophagus(1), stomach(9), 
small intestine(16), mesenteric lymph node(2), appendix(2), colon(18), rectum(1) and 
anus(2). For more details we refer to the General Materials & Methods of this manuscript, 
described earlier. The table summarizing patients and biopsies selected for this study are 
presented in Appendix III. 
 
RESULTS 
 
In addition to small and isolated (sub-) mucosal granulomas, we found granulomas in the 
follicle (GIF) centre of mucosa-associated lymphoid tissue in samples of 11 out of 23 
investigated pCD patients. GIFs were found in more than half of procedures in these 11 
patients with GIFs. Namely, 53% of endoscopic and 80% of surgical procedures showed 
GIFs in sampled tissue. The presence of GIFs was independent of CD-associated SNPs in the 
NOD2, ATG1 and ATG16L1. Morphological features typical of BS granulomas were more 
often observed in pCD with GIFs (Table R1.2.1). The median age at disease onset was 14 
years (range 9 to 18 years) for pCD patients with GIF, which is slightly younger than 16 
years (range 9 to 19 years) for pCD patients without GIFs. A CD4 over CD8 predominance of 
T-lymphocytes was virtually always observed in patients with and without GIF. We observed 
more CD20+ B-lymphocytes in and around classical granulomas of GIF patients. We also  
92 
 
observed more prominent RIP2, IL23R, IFNγ, IL1β and IL17 expression in GIF patients. 
(Table R.1.2.2). GIFs could be distinguished from granulomas with lymphocytic coronas by 
visualisation of the follicle mantle by CD20 staining (Figure R.1.2.1F). 
 
 
  
 
 
Table 1: Morphology pCD with GIF (n=11) pCD without GIF (n=12) 
Focal Microgranulomas + ++ 
(Langhans type) MGCs +++ ++ 
Lymphocytic Corona ++ + 
Polycyclic Architecture ++ + 
LEMGC + - 
MGC death + - 
Refractive Inclusions + - 
Sclerosis Surrounding Tissue + - 
 
Table R.1.2.1. Features were scored by using a semiquantitative scoring system: -, absent; +, 
sporadic; ++, moderate; +++, prominent. Biopsy material of 23 patients was available. 
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Figure R.1.2.1. IHC staining of GIF in intestinal MALT of pCD patients A) Increased RIP2 expression in 
mononuclear cells in and around a GIF, but only sporadic RIP2 staining in the MGCs in the granuloma 
centre. B) IL23R staining is moderate in both MGCs and mononuclear cells. C) IL1βstaining is present 
in the majority of investigated GIFs. D) IFNγstaining is prominent in the majority of GIFs. E) 
moderate IL17 staining is observed around the GIF, but the MGCs in the centre of the granuloma 
show only sporadic staining. F) CD20 staining to distinguish between coronal granulomas and GIFs. 
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DISCUSSION 
 
The observation of GIFs in addition to traditional (sub-) mucosal granulomas might be 
associated with increased diseases severity. To determine whether it also is a useful 
prognostic feature for CD, long term follow-up of a greater amount of patients is necessary. 
Patients with GIFs have larger granulomas with more MGCs, lymphocytic coronas around 
granulomas and polycyclic granuloma architecture. Furthermore, LEMGC, an important 
feature of BS granulomas, was exclusively found in pCD patients with GIFs. Younger age at 
disease onset, Th17 involvement and increased IFNγ, IL23R and RIP2 expression are also 
good arguments for a more severe inflammation of the bowel.The presence of GIFs was 
independent of CD-associated SNPs in NOD2, ATG1 and ATG16L1. This is understandable, 
because CD is a disease that results from a complex interplay between environmental and 
susceptibility factors related to macrophage function. Remarkably, extensive disease affecting 
anus (6), appendix (2), oropharynx (1) and/or lymph nodes (2) was seen in 8 out of 11 pCD 
patients with GIF and in none out of 12 pCD patients without GIF. The CD subtype with anal 
involvement is associated with a considerable increase in disease morbidity. These four 
locations in the gastro-intestinal tract are associated with a higher bacterial load (anus/rectum 
and appendix/caecum) or a microbial flora different from the ileocolon (oropharynx), or may 
contain a higher amount of bacteria due to increased bacterial translocation (lymph nodes) 
However it should be noted that the chance of detecting GIFs is subject to sampling 
variability, especially when endoscopic biopsies are assessed. This is an important factor 
when investigating the relevance of GIF in CD biopsies in the future. GIF in CD may indicate 
more severe morbidity. Frequency and prognostic use should be investigated on a larger 
population. It remains unclear how these lesions are formed: it might be interesting to attempt 
pathogen detection in GIFs. Laser capture microdissection of frozen tissue is useful to look 
for genomic material of intestinal microbes at specific lesions. 
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Table 2: Immunohistochemistry pCD with GIF (n=11) pCD without GIF (n=12) 
CD4+ > CD8+ +++ +++ 
CD20+ B-lymphocytes ++ + 
IL23R+ MML & T-lymphocytes ++ + 
RIP2+ MML +++ ++ 
TNFα+ ++ ++ 
IL1β+ MML +++ ++ 
IFNγ+ MML & T-lymphocytes +++ ++ 
IL6+ MML & T-lymphocytes + + 
IL10+ MML & T-lymphocytes + + 
IL17+ MML & T-lymphocytes ++ + 
TGFβ+ T-lymphocytes + + 
 
Table R.1.2.2. Features were scored by using a semiquantitative scoring system: -, absent; +, 
sporadic; ++, moderate; +++, prominent. Biopsy material of 23 patients was available. 
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CHAPTER 2.1: 
MORPHOLOGIC AND IMMUNOHISTOCHEMICAL 
CHARACTERIZATION OF GRANULOMAS IN THE  
NUCLEOTIDE OLIGOMERIZATION DOMAIN 2-RELATED DISORDERS 
BLAU SYNDROME AND CROHN DISEASE 
(PUBLISHED RESEARCH ARTICLE)  
This chapter consists of 2 parts, the first part is a published research article on 6 BS and 7 
pCD patients’ biopsies containing granulomas. This article is the first morphological and IHC 
description of several BS patients and uses a comparative gene based approach to gain insight 
in granuloma pathology. In it we introduce polycyclic granuloma architecture and LEMGC as 
distinct features of BS and mention the presence of GIF in secondary lymphoid tissue of BS 
and NOD2+ pCD patients. These initial findings stimulated us to hypothesize the first two 
morphological features, together with IHC detection of IL17 in the affected tissue, are of 
diagnostic relevance for auto-inflammatory etiology in sarcoid granulomas and the latter is of 
prognostic use for idiopathic granulomatous inflammatory diseases in children and adults. 
We decided to further investigate these two hypotheses in NOD2-related AS (Chapter 2.2) 
and pCD (Chapter 1.2) respectively and validate them in other granulomatous inflammatory 
diseases with wild type NOD2 (Results Section 3) by assessing the same standardized 
granuloma set of morphological and IHC features used in the following published research 
article. In Chapter 2.3 we will focus on the outcome of LEMGC in NOD2-related diseases, as 
it is associated with MGC death and NOD2 contains CARDs. The following article briefly 
mentions new insights that determined our further explorations. Indeed, remarkably, LEMGC 
and IL17 expression in polycyclic granulomas with lymphocytic coronas were dominant 
features in BS and thus possibly to be linked with an auto-inflammatory signature. This 
merits further investigation. The second part is an extension by additional internationally 
collected PS and locally selected pCD patients’ biopsies. Further details and NOD2 variants 
of these additional patients are listed in a table in appendices II (PS) and III (pCD). 
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In addition to the data of the published research article, we are supplying additional findings 
here regarding the presence of NOD2 variants and a possible relation to pathological 
characteristics of granulomatous inflammation in PS and pCD individually. Candidate PS and 
auto-inflammatory syndrome patients were genotyped for diagnostic purposes to detect the 
BS. The spectrum of PS comprises NOD2+ (BS/EOS) and NOD2-PS (IOPSG, ATPS and 
UPS). Whole gene sequencing revealed disease-associated mutations in NOD2 in 11 BS 
patients and not in the other 9 PS patients. The most common BS-associated amino acid 
substitution on position 334 (R334Q/W) was found in 73% of the investigated BS patients. 
One BS patient carried both R334Q associated with BS and L1007fsinsC-/C associated with 
CD and a new (homozygous) BS-associated mutation L454V was found in another BS 
patient, in the following article. The other two BS patients carried G481D and C495Y 
associated with BS respectively. In addition to the 4 IOPSG patients collected through the 
Blau Registry and reported in 2007, one new IOPSG patient was recently referred to us in 
2011 after it was recognized by Dr. Lenora M. Noroski from the Texas Children’s Hospital in 
Dallas, Texas, USA. CD-associated SNPs (R702W, G908R and L1007fsinsC-/C) in NOD2 
were detected in 30% of investigated pCD patients. The frameshift mutation L1007fsinsC-/C 
was the most common (70%), followed by R702W (40%) and G908R (15%), in the 
investigated NOD2+ pCD patients. Some additional biopsy tissue from BS patients has been 
collected afterwards.This comparative study reveals auto-inflammatory BS granulomas have 
a distinct morphological and IHC profile compared to NOD2+ pCD, supporting the gain-of-
function hypothesis for systemic granulomatous inflammation in BS. Furthermore 
unpublished observations listed below suggest BS mutations are associated with distincts 
granuloma features (polycyclic granuloma architecture, LEMGCs and Th17 involvement) 
may be of diagnostic relevance for granulomatous auto-inflammation in children with 
idiopathic granulomatous disease: the complete pathological triad was never observed in 
NOD2- PS types IOPSG and UPS. We have summed up the amount of patients and their 
most predominant granuloma stages in the most comprehensible fashion. This is difficult 
because morphological granuloma stages are not disease-specific, nor exclusively present. 
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We have chosen to compare NOD2+ PS (BS) to NOD2- PS, and not BS to IOPSG or ATPS, 
because these entities are both extra-ordinary and extremely rare, not to mention UPS:  
BS: Characterized by polycyclic coronal granulomas with LEMGC and atypical cell death. 
Chronic synovitis without granulomas was found at disease onset in BS patient WILM.1.S1. 
MRGs were only found in panniculitis of BS patient LEUVEN.7.P with novel mutation. 
Epithelioid microgranulomas were exclusively found in BS patient BUE.2.P. 
Mature granulomas were never exclusively observed in BS patients. 
Coronal granuloma was the lowest granuloma stage in 6 out of 11 BS patients. 
Not sclerosing granuloma, but sclerosis of surrounding tissue in 3 out of 11 BS patients. 
Polycyclic granuloma was the highest granuloma stage in 7 out of 11 BS patients. 
GIF were found in the spleen of ZAGREB.1.P and the lymph node of WILM.1.P  
NOD2- PS: Mixed collection comprising IOPSG characterized by MRGs/microgranulomas. 
Panniculitis without granulomas found at disease onset in 3 out of 8 NOD2- PS patients. 
MRGs were found in subcutis or liver at disease onset in 4 out of 8 NOD2- PS patients. 
Epithelioid microgranuloma was the highest stage in 4 out of 8 NOD2- PS patients. 
Mature granuloma was the highest granuloma stage in 2 out of 8 NOD2- PS patients. 
Coronal granulomas were only found in spleen and synovium of IOPSG patient PARIS.2.P 
Sclerosing granulomas were only found in the kidney of a pulmonary NOD2- PS patient. 
Polycyclic granuloma was the highest granuloma stage in 2 out of 8 NOD2- PS patients. 
GIF were only found in the spleen of IOPSG patient PARIS.2.P. 
CD-associated NOD2 SNPs/frameshift mutations do not drastically affect granuloma 
morphology. NOD2+ pCD patients predominantly had epithelioid microgranulomas and 
mature granulomas in the intestinal mucosa and are referred to below as published. Marked 
sclerosis of the surrounding tissue is in accordance with the association between CD-
associated SNPs in NOD2 and the stenotic subtype of CD which has a worse prognosis. Also 
NOD2- pCD patients predominantly had epithelioid microgranulomas and mature 
granulomas in the intestinal mucosa. Polycyclic granuloma architecture and lymphocytic 
coronas were found to be associated with the presence of GIF and not NOD2 SNPs. 
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Lymphocyte emperipolesis in MGCs was exclusively observed in pCD patients with GIF. To 
summarize CD is characterized by smouldering granulomatous inflammation of the intestine. 
NOD2+ pCD: stenotic subtype associated with sclerosis of the surrounding intestinal tissue 
Chronic enteritis without granulomas was found at disease onset in all NOD2+ pCD patients. 
MRGs were never found in NOD2+ pCD patients. 
Epithelioid microgranuloma was the highest granuloma stage in Case 12. 
Mature granuloma was the lowest granuloma stage in 4 out of 7 NOD2+ pCD patients. 
Coronal granuloma was the highest granuloma stage in Case 7. 
Not sclerosing granuloma, but surrounding tissue in 4 out of 7 NOD2+ pCD patients. 
Polycyclic granulomas were exclusively found in Case 9. 
GIFs were found in MALT, appendix or lymph nodes in 3 out of 7 NOD2+ pCD patients. 
NOD2- pCD: mature granulomas that occasionally exhibit auto-inflammatory features  
Chronic enteritis without granulomas was found at disease onset in all NOD2- pCD patients. 
MRGs were never found in NOD2- pCD patients. 
Epithelioid microgranuloma was the highest stage in 3 out of 16 NOD2- pCD patients. 
Mature granuloma was the lowest granuloma stage in 11 out of 16 NOD2- pCD patients. 
Coronal granuloma was the highest granuloma stage in 4 out of 16 NOD2- pCD patients. 
Not sclerosing granuloma, but surrounding tissue in 1 out of 16 NOD2- pCD patients. 
Polycyclic granuloma was the highest granuloma stage in 8 out of 16 NOD2- pCD patients. 
GIFs were found in MALT, appendix or lymph nodes in 7 out of 16 NOD2- pCD patients. 
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CHAPTER 2.2: 
R702W IN NUCLEOTIDE OLIGOMERIZATION DOMAIN 2  
IS LINKED WITH AUTO-INFLAMMATORY FEATURES IN CLASSIC 
SCLEROSING LUNG SARCOIDOSIS 
(EXTENDED ABSTRACT) 
 
BACKGROUND: The R702W (rs2066844) polymorphism in the nucleotide 
oligomerisation domain 2 (NOD2) protein, an intracellular pathogen sensor in innate 
immune cells that can induce inflammation and autophagy, is linked with severe adult 
sarcoidosis (AS) of the lung. METHODS: Granulomas in paraffin-embedded biopsies of 
30 pulmonary (AS-P) and 13 extra-pulmonary (AS-EP) AS patients of the last decade 
were studied by a standardized set of morphological features, immunohistochemistry 
for HLA-DR, CD68, CD4, CD8, CD20, IL23R and cytokines TNFα, IFNγ, IL6, IL10, 
IL17, TGFβ and determining NOD2 variants p.R702W (rs2066844), p.G908R 
(rs2066845) and p.Leu1007fsX1008 (rs2066847). RESULTS: IL17+ sclerosing 
aggregates (77%), lymphocyte emperipolesis in multinucleated giant cells (LEMGC) 
(62%), granuloma-in-follicles (GIF) (31%) and NOD2 variants (20%) were more 
frequent in AS-P than AS-EP patients: 1 hepatic AS-EP and 5 AS-P patients with 
LEMGC carried heterozygous p.R702W, 1 isolated caridal AS-EP patient with LEMGC 
carried heterozygous p.G908R and 1 hepatic AS-EP without LEMGC carried 
heterozygous p.Leu1007fsX1008. Disease set on below median age in all patients 
carrying NOD2 variants. 6 renal AS-EP patients had wild type NOD2 (100%), low 
IL23R (100%), late disease onset (100%), no pathognomonic features (83%), inverse 
CD4:CD8 (60%) and no GIF (100%).  CONCLUSION: Our study confirms mixed 
Th1/Th17 involvement, sclerosing granuloma aggregates and rs2066844 are observed in 
classic AS-P. In AS-P rs2066844 was specifically associated with LEMGC, a feature of 
granulomatous auto-inflammation. GIF were only found with sclerosing granulomas.    
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INTRODUCTION 
 
Sarcoidosis is an exclusion diagnosis of idiopathic multisystemic granulomatosis that 
typically affects the lung and shows a lymphatic distribution pattern, but can affect any part 
of the body.
1
 Extrapulmonary sarcoidosis is atypical but can be observed as well: e.g. renal 
sarcoidosis or rare hereditary types of pediatric sarcoidosis such as NOD2-related Blau 
syndrome (BS) characterized by a clinical triad of skin, eye and joint disease. In the latter, 
gain-of-function mutations in the central NOD/NACHT domain are believed to result in a 
hyperactive intracellular pathogen sensor resulting downstream in constitutive NF-κB 
activation, pro-inflammatory gene transcription, caspase activation and autophagy 
stimulation.
2-5
 On the other hand, loss-of-function NOD2 variants are believed to render the 
innate immune system lethargic in maintaining the balance with gut microbiota, contributing 
to Crohn’s disease (CD) that typically affects intestinal locations with a higher bacterial load. 
Variance in autophagy-related genes such as ATG16L1, ATG1 and IRGM, anti-inflammatory 
IL10 and IL23R necessary for Th17 maintenance have also been related to CD development. 
The CD-associated NOD2 variant R702W is associated with severe pulmonary sarcoidosis.
6 
We have described extensive lymphocyte emperipolesis in multinucleated giant cells (MGCs) 
in epithelioid granulomas with polycyclic architecture and lymphocytic coronas in a modest 
selection of BS patients collected through international and interdisciplinary collaboration. 
Their extra-ordinary genetic background is in line with the peculiar features observed their 
large epithelioid granulomas, Th1 and Th17 cytokine expression profile and high disease 
morbidity. BS is a naturally occurring study model for granulomatous auto-inflammation and 
therefore these extra-ordinary features might be relevant to gain insight in the enigmatic 
exclusion diagnosis of sarcoidosis, a collection of idiopathic granulomatous diseases in 
children and adults, which is associated with mixed Th1 and Th17 involvement.  
In addition, we have described the histopathology of granuloma-in-follicles (GIF) in the 
secondary lymphoid tissue of NOD2-related pediatric granulomatous diseases BS and CD. 
GIF were observed in splenic and submandibular lymph node tissue in 33% of previously 
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reported BS patients and in splenic tissue in 25% of previously reported IOPSG patients. 
IOPSG is a new entity discovered through the international Blau Registry and clinically the 
most challenging differential diagnosis from BS, for which a causative mutation has not been 
identified yet. GIF were also observed in the mesenteric lymph node and mucosa-associated 
lymphoid tissue (MALT) of appendix, colon and ileum in 43% of previously reported 
pediatric CD patients with NOD2 variants and MALT in appendix, caecum, colon, ileum and 
rectum in 44% of unreported pediatric CD patients without NOD2 variants. Our data suggest 
GIF are not specifically associated with NOD2 status, but with morbidity and outcome. 
Here we use the same standardized set of histopathological features and IHC stainings to 
investigate the cellular composition, cytokines profile and death-related proteins in 
epithelioid granulomas.  
 
MATERIALS AND METHODS 
 
We retrospectively selected all available biopsy tissue containing granulomas of well 
documented adult sarcoidosis patients from the pathological archive of the University 
Hospitals Leuven since 2003. Special attention was paid to BS-related features such as 
polycyclic granuloma architecture, lymphocytic coronas around granulomas and lymphocyte 
emperipolesis in MGCs (LEMGC) and cytokines related to Th17 formation. We also assessed 
for the presence of GIF in secondary lymphoid tissue in spleen, mediastinal lymph nodes and 
bronchus-associated lymphoid tissue (BALT) and collected clinical parameters for disease 
activity, additional organ involvement, morbidity and outcome. Furthermore, we investigated 
the outcome of LEMGC by assessing the morphological features of cell death and IHC 
staining for external and internal apoptosis pathway proteins. Our initial selection (A) of 
23AS patients revealed p.R702W (rs2066844) in 2 AS-P patients with LEMGC, but 
p.Leu1007fsX1008 (rs2066847) or  p.G908R (rs2066845) were never detected. We have 
omitted one outlier carrying heterozygous p.Leu1007fsX1008 (rs2066847), who exhibited 
granuloma annulare on a skin biopsy, the only one available to us. To confirm the association 
118 
 
between R702W and AS-P the study population was expanded (B) and 21 additional (17 
AS-P and 4 AS-EP) patients were genotyped for NOD2 variants p.R702W 
(rs2066844), p.G908R (rs2066845) and p.Leu1007fsX1008 (rs2066847). For more 
details we refer to the General Materials & Methods of this manuscript, described earlier. The 
table summarizing patients and biopsies selected for this study are presented in Appendix IV. 
 
RESULTS 
 
IL17+ sclerosing aggregates (77%), LEMGC (62%), granuloma-in-follicles (GIF) 
(31%) and NOD2 variants (20%) were more frequent in AS-P than AS-EP patients: 1 
hepatic AS-EP and 5 AS-P patients with LEMGC carried heterozygous p.R702W, 1 isolated 
cardial AS-EP patient with LEMGC carried heterozygous p.G908R and 1 hepatic AS-EP 
without LEMGC carried heterozygous p.Leu1007fsX1008. Disease set on below median age 
in all patients carrying NOD2 variants. 6 renal AS-EP patients had wild type NOD2 (100%), 
low IL23R (100%), late disease onset (100%), no pathognomonic features (83%), inverse 
CD4:CD8 (66%) and no GIF (100%). These results indicate Th17, NOD2 genotype and 
sclerosing granuloma aggregates are more important in the pathogenesis of classic AS-P than 
of AS-EP. In addition, we found NOD2 variants in 5 out of 12 AS patients with liver 
involvement and heterozygous p.G908R (rs2066845) in a peculiar myocardial AS patient 
with recurrence after heart transplantation. As mentioned in the general discussion, NOD2 
genotype and LEMGC might be predictive of transplantation outcome. To conclude we 
would like to highlight that the BS-associated pathological triad of granulomatous auto-
inflammation is associated with classic sclerosing AS-P specifically. Although polycyclic 
granuloma architecture and lymphocytic coronas were often observed with the other 2 
features, they were only sporadically the predominant histologic phenotype in AS patients. 
The most common histologic phenotype was aggregates of granulomas surrounded and 
divided by concentric sclerosis, hence not exhibiting polycylic architecture. We confirm the  
NOD2 variant R702W is associated with severe AS-P, as reported by Sato et al in 2010.  
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The histopathological spectrum of granulomas in the initial selection of 23 AS patients: 
Pulmonary AS (AS-P): sclerosing (polycyclic) granuloma aggregates with LEMGC. 
Chronic pneumonitis without granulomas was not found at disease onset in AS-P patients. 
MRGs were never found in AS-P patients. 
Epithelioid microgranulomas were never found in AS-P patients. 
Mature granulomas were the highest granuloma stage in 2 (R702W) out of 13 AS-P patients. 
Coronal granuloma was the lowest granuloma stage in 2 out of 13 AS-P patients. 
Sclerosing granulomas and surrounding tissue were found in 10 out of 13 AS-P patients. 
Polycyclic granuloma was the highest granuloma stage in 7 out of 13 AS-P patients. 
GIFs were found in BALT or lymph nodes in 4 out of 13 AS-P patients. 
Extrapulmonary renal AS (AS-EP-R): dry mature granulomas, no pathognomonic features 
Chronic nephritis without granulomas was not found at disease onset in AS-EP-R patients. 
MRGs were never found in in AS-EP-R patients. 
Epithelioid microgranuloma was the highest granuloma stage in 1 out of 5 AS-EP-R patients. 
Mature granulomas were the highest granuloma stage in 3 out of 5 AS-EP-R patients. 
Coronal granulomas were never found in pulmonary in AS-EP-R patients. 
Sclerosing granulomas and surrounding tissue were never found AS-EP-R patients. 
Polycyclic granulomas were exclusively found in 1 out of 5 AS-EP-R patients. 
GIFs were never found in secondary lymphoid tissue of AS-EP-R patients. 
Extrapulmonary extrarenal AS (AS-EP-ER): (primary) idiopathic granulomatous diseases 
Primary sclerosing cholangitis was found at disease onset in 1 out of 4 AS-EP-ER patients. 
MRGs were never found in AS-EP-ER patients. 
Epithelioid microgranulomas were never found in AS-EP-ER patients. 
Mature granulomas were never the highest granuloma stage in AS-EP-ER patients. 
Coronal granuloma was the lowest granuloma stage in 2 out of 4 AS-EP-ER patients. 
Sclerosing granulomas were exclusively found in the only multi-systemic AS-EP-ER patient. 
Polycyclic granuloma was the highest granuloma stage in 3 out of 4 AS-EP-ER patients. 
GIFs were exclusively found in the spleen of the only multi-systemic AS-EP-ER patient. 
120 
 
DISCUSSION 
 
AS-EP-ER patients remain a collection of idiopathic granulomatous diseases. Our selection 
included only one AS-EP-ER patient with biopsy-proven multisystemic granulomatosis. She 
also was the only AS-EP-ER patient exhibiting auto-inflammatory features and GIF. Most 
other AS-EP patients did not exhibit any pathognomonic features of diagnostic relevance. Of 
more interest however, is that the LEMGC phenotype was only observed in this patient with a 
prominence and number comparable to the LEMGC phenotype of BS reported in Chapter 2.1. 
All other AS patients exhibiting LEMGC showed a phenotype more comparable to the 
description of LEMGC in pCD granulomas reported in Chapter 2.1. Although this patient was 
only 36 years at disease onset, the investigated NOD2 SNPs could not be detected. It remains 
to be clarified whether any BS associated mutations might explain the BS-like granuloma 
phenotype she exhibits (although sclerosing aggregates typical for AS were also present). 
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CHAPTER 2.3: VARIANT NOD2 
OUTCOME OF LYMPHOCYTE EMPERIPOLESIS IN MULTINUCLEATED 
GIANT CELLS IN NUCLEOTIDE OLIGOMERIZATION DOMAIN 2- 
RELATED DISORDERS 
(ARTICLE IN PREPARATION) 
BACKGROUND: Blau Syndrome (BS) is a systemic granulomatous disease caused by 
gain-of-function mutations in NOD2.  Crohn’s disease (CD) is associated with intestinal 
granulomas, and loss-of -function NOD2 variants, one of which was recently associated 
with severe pulmonary adult sarcoidosis (AS) as well.  METHODS: To describe the 
histopathological phenotype of multinucleated giant cells (MGCs) exhibiting 
lymphocyte emperipolesis (LEMGC) in BS, pediatric CD and AS granulomas, we 
selected 25 samples after screening 13 PS, 23 CD and 23 AS patients for LEMGC to 
stain with H&E and monoclonal antibodies for leukocyte markers (CD68, CD4, CD8, 
CD20), cytokines (IFNγ, IL6, IL10, IL17, TGFβ, TNFα) and death-related proteins 
(Bcl2, Fas, FasL, activated Caspase3).  RESULTS: We observed emperipoletic vacuoles 
containing ingested cells are transported to the MGC centre, disseminate into macro- 
and microvesicles to eventually leave behind accumulating degenerative remnants. 
Emperipolesis was prominent in BS and sporadic in AS granulomas, and typically 
associated with MGC death (EAMD). As reported earlier, emperipolesis was sporadic in 
pCD granulomas and often associated with crystalline inclusions (EACI) in pCD. CD4+ 
T-cells were selectively ingested, suggesting this is not a cytotoxic response of CD8+ T-
cells. Ingestion of CD20+ B-cells was not seen. Macro-, microvesicles and degenerative 
remnants stained positive for IL6 and IL17, and sporadically for TGFβ. IFNγ, TNFα, 
IL1β and IL23R were expressed by both lymphocytes and MGCs, hence vesicular 
staining pattern could not be distinguished from cellular staining. Bcl2 expression was 
common in lymphocytes and the surrounding tissue, but rare in MGCs. Fas+ MGCs 
and FasL+ emperipoletic lymphocytes were usually present when EAMD was observed. 
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Caspase3 activation was sporadically present in lymphocytes, but hardly ever in MGCs. 
CONCLUSION: Our data show that lymphocyte emperipolesis within other cells is 
prominent in BS granulomas, associated with caspase-independent MGC death and 
might be of diagnostic use for granulomatous auto-inflammation in children and adults. 
 
INTRODUCTION 
 
In the last decade, the NOD (nucleotide-binding oligomerisation domain) like receptor (NLR) 
family of molecules has been found to play a pivotal role in an expanding number of 
monogenic and polygenic human inflammatory diseases. The Blau syndrome (BS) is a 
monogenic auto-inflammatory disease characterized by a triad of granulomatous uveitis, 
arthritis and dermatitis and caused by gain-of-function mutations in the NOD/(NAIP, CIITA, 
HET-E, TP-1) (NOD/NACHT) domain of the NOD2 protein.
1, 2 
Loss-of-function single 
nucleotide polymorphisms (SNPs) R702W and G908R and the frameshift mutation 
L1007fsinsC-/C in the leucine rich repeats (LRR) domain of the NOD2 gene render 
susceptible to the development of Crohn’s disease (CD), a polygenic and multifactorial 
inflammatory bowel disease associated with (sub-)mucosal granulomas.
3, 4
 Recently, the CD-
associated R702W SNP in NOD2 has been associated with severe pulmonary sarcoidosis as 
well.
5
 Furthermore, two recent studies have uncovered an autophagy-mediated immune 
response to bacteria through their detection by NOD receptors and SNPs in autophagy-related 
genes IRGM  and ATG16L1 have been associated with CD.
6
 Historically, the term 
emperipolesis was proposed by Humble et al. in 1956 to describe "the temporary presence of 
one cell within another's cytoplasm."
7
 This definition implies that the engulfed cell remains 
viable, but this was recently challenged by Xia et al. When the internalized cell eventually 
dies, the term ‘entosis’ is used to describe the phenomenon of emperipolesis associated with 
death of the target cell.
8
 Emperipolesis is considered a diagnostic feature of Rosai-Dorfman’s 
disease a.k.a sinus histiocytosis with massive lymphadenopathy.
9
 Recently, we have 
associated this phenomenon with Pediatric Granulomatous Arthritis a.k.a. the Blau syndrome 
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(BS) as well. We reported that lymphocytes emperipolesis in multinucleated giant cells 
(MGCs) is a prominent feature of BS granulomas. We suspect this phenomenon is related to 
the interaction between NOD2 and the autophagy-pathway. Therefore, we screened for the 
presence of lymphocyte emperipolesis in MGCs (LEMGC) in the epithelioid granulomas of 
21 pediatric sarcoidosis (PS), 23 pediatric CD (pCD) and 23 adult sarcoidosis (AS) patients.  
 
MATERIALS AND METHODS
 
 
Patients 
All biopsies from 21PS patients, 23 pCD patients and 23AS patients were examined for the 
presence of LEMGC and its outcome. LEMGC was found in 11 samples from 8 PS patients, 
9 samples from 6 pCD patients and 10 samples from 9 AS patients. All 21 PS patients were 
of European or North-American descent and were recruited through the International Blau 
Registry.
10 
Remarkebly, LEMGC was never found in skin biopsies of PS patients, the 
conventional site for diagnostic biopsies. 8 PS patients exhibited LEMGC inside epithelioid 
granulomas in at least one of their biopsies. The median age at disease onset of these 8 PS 
patients was 3 years, from 1 to 17 years. The PS group consisted of 11 PS biopsies with 
LEMGC, including a spleen and a kidney, two synovial samples, two lymph nodes, three 
liver samples and two bone marrow cores. The clinical triad was present in all selected BS 
patients except case 5 and entirely absent in all three unclassified pediatric sarcoidosis (UPS) 
cases. UPS case 6 suffered from isolated hepatic sarcoidosis that recurred after liver 
transplantation and was the subject of a case report.
11
 All 23 pCD patients were of European 
descent and diagnosed with CD at the Gasthuisberg University Hospital in Leuven. 6 pCD 
patients exhibited LEMGC inside epithelioid granulomas in at least one of their biopsies. All 
selected pCD patients had a severe disease phenotype that extended beyond the ileum and 
colon, affecting mouth, anus, appendix or lymph nodes. The median age at disease onset of 
these 6 pCD patients was 14 years, from 9 to 18 years. The pCD biopsies comprised 9 
samples with LEMGC, including a lymph node, two colon, two ileum, two appendices and an 
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oral and an anal sample. All 23 AS patients were of European descent and diagnosed with AS 
at the Gasthuisberg University Hospital in Leuven. Nine AS patients exhibited LEMGC in 
epithelioid granulomas in at least one of their biopsies. The median age at disease onset of 
these nine AS patients was 36 years, from 24 to 62 years. Except for case 22, all AS patients 
exhibiting LEMGC suffered from pulmonary sarcoidosis (AS-P). Case 22 suffered from 
extrapulmonary sarcoidosis (AS-EP) confined to the liver and the spleen. Except for case 16, 
all AS patients exhibiting LEMGC had multisystem involvement. There were 10 AS biopsies 
with LEMGC, including three lymph nodes, three lung samples and a bronchus, kidney, liver 
and spleen sample. All biopsies were embedded in paraffin and obtained after informed 
consent. Biopsy sites and NOD2 genetic variants for all patients are depicted in Table 
R.2.3.1.  
 
Genotyping 
The genotyping of PS patients was done as previously described results were summarized in 
Table 1.
10
 Genomic DNA was obtained directly from collaborating sites or was extracted 
from blood samples. For genotyping, genomic DNA was subjected to polymerase chain 
reaction (PCR) amplification using either FastStart Taq DNA polymerase with GC-Rich 
solution (Roche Diagnostics, Mannheim, Germany) or Optimase Polymerase (Transgenomic, 
Omaha, NE), and a touchdown PCR strategy. Primers were designed to amplify regions of 
the NOD2 gene containing the known Blau syndrome mutations encoding substitutions at 
position 334, known common non–disease-associated polymorphisms, and the 3 Crohn's 
disease (CD)–associated mutations. The resultant PCR products were subjected to denaturing 
high-performance liquid chromatography (dHPLC) analysis to screen for the presence of 
mutations/polymorphisms (WAVE; Transgenomic). Amplicons that screened positive by 
dHPLC were subsequently subjected to direct DNA sequencing (in both directions) to 
confirm the mutation/polymorphism. If no Blau syndrome mutation was detected, the entire 
coding region of exon 4 was sequenced in both directions to identify any unknown mutations 
present in the sample. Because UPS case 8 was retrospectively selected from the pathological 
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archive and had moved away, he couldn’t be contacted to request genotyping. Genotyping of 
pCD patients was done as described earlier.
12
 DNA was isolated from whole venous blood 
using a salting out procedure and was stored at −80°C. Patients were genotyped for the three 
main SNPs in NOD2 associated with CD (Arg702Trp, Gly908Arg, and Leu1007InsC) using 
polymerase chain reaction restriction fragment length polymorphisms. DNA restriction 
fragments were separated on agarose gels and visualised by ethidium bromide. 
 
MORPHOLOGY 
 
To study the morphology of LEMGCs, 5 µm H&E tissue slides were stained. For specific 
biopsy sites and techniques, adjusted protocols were used to preserve better morphology 
better: B5 fixation was used for bone marrow cores and Carnoy fixation for endoscopical 
biopsies of the gastro-intestinal tract. All other tissue specimens were formalin-fixed and cut 
at 3 µm. We studied a standardized empiric set of morphological features of MGCs 
exhibiting emperipolesis, including the presence of chromatin condensation (pyknosis), 
nuclear fragmentation (karyorrhexis), cell shrinkage with cytoplasmic condensation 
(hypereosinophilia), autophagic vacuolization (macrovesicles), autophagosome accumulation 
(microvesicles) and the formation of refractive crystalline inclusions. Also we investigated 
the presence of intragranulomatous fibrosis and fibrinoid necrosis in the granuloma centre. 
 
Immunohistochemistry (IHC) 
Monoclonal antibodies (MoAbs) to CD4 (Dako M0716, clone MT310) and CD8 (Dako 
M7103, clone C8/144B) for T-lymphocytes, CD20 (Dako M0755, clone L26) for B-
lymphocytes, and IL23R (Abcam ab53656, clone IL23A/IL23) for IL23-responsive 
leukocytes were applied to define the leukocytic subsets. MoAbs targeting inflammatory 
cytokines and chemokines such as TNFα (Peprotech 500-M26, clone K175 with Dako 
Linker), IFNg (Abcam ab9657), IL1β (Abcam ab8320, clone 11E5), IL6 (Abcam ab9324), 
IL10 (Serotec MCA926, clone B-S10), IL-17 (R&D systems MAB3171, clone 41802) and 
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TGFβ (Novocastra NCL-TGFB, clone TGFB17) were applied. To investigate cell death 
pathways, MoAbs targeting Bcl2 (Dako M0887, clone 124), Fas (Santa Cruz sc-8009, clone 
B10) and activated Caspase 3 (Abcam ab32042, clone E83-77) and a polyclonal antibody 
targeting FasL (Santa Cruz sc-834, clone N20) were used. The signal amplification step was 
applied with Dual Envision (Dako) that uses the DiAminoBenzidine chromogen for 
visualization under the light microscope. Enough biopsy material to execute all stainings was 
available for the pCD and AS patients. Material for IHC was limited for BS patients and 
unavailable for BS case 2. Adjusted counts are between brackets in Table R.2.3.2.  
 
Semiquantitative pathological scoring 
The semiquantitative scores in Table R.2.3.2 were calculated based on individual patients, 
and not on individual biopsies. Each slide was scored by two independent investigators (CEIJ 
and VJD for BS, CEIJ and GDH for pCD and CEIJ and EV for AS). Dichotomous features 
were given a score of 0 (negative) or 1 (positive), ordinal variables were given a score of 0 
(negative), 1 (mild), 2 (intermediate) or 3 (dense). All morphological and IHC features were 
treated as dichotomous. The patient score was calculated as the mean of the scores of all 
biopsies of an individual patient, then the group (PS, pCD or AS) score was expressed as the 
mean score of all patient scores. For dichotomous variables a group score x=0 was depicted 
by (-) meaning the feature was never observed, 0<x≤1/3 is depicted by (+) sporadically 
present, 1/3<x≤2/3 is depicted by (++) common and 2/3<x≤1 is depicted by (+++) prominent 
in that patient group. 
 
RESULTS 
 
Lymphocyte emperipolesis is associated with BS, AS-P and extensive CD manifestation  
NOD2 variants were detected in 86% of PS exhibiting LEMGC. LEMGC was prominent in 
individual PS patients, occurring in the majority of biopsies containing granulomas, and in 
the majority of granulomas containing MGCs. As reported earlier, LEMGC was clearly 
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associated with Blau mutations in NOD2 (G481D, R334Q, L454V and R334W), as it was 
present in extra-dermal biopsy specimen of 5 out of 9 BS patients. LEMGC was absent in all 
5 IOPSG patients, the most important differential diagnosis from BS, but present in 3 out of 5 
unclassified PS patients without Blau mutations. Remarkebly, UPS case 7 carried CD-
associated G908R and presented with localized granulomatous inflammation of the dermis, 
deep connective tissue and a lymph node from the elbow region, reminding of extra-intestinal 
CD manifestation although not abdominally localized. On the other hand, NOD2 variants 
were detected in 33 % of pCD and 22 % of AS exhibiting LEMGC. LEMGC was sporadic in 
the majority of individual pCD and AS patients, occurring in only few biopsies containing 
granulomas, and in only few granulomas containing MGCs. There was no clear relation 
between the presence of LEMGC in epithelioid granulomas and CD-associated SNPs in 
NOD2 (R702W, G908R and L1007fsinsC-/C) in pCD, as it was seen in only 2 out of 7 
NOD2+ and 4 out of 16 NOD2- pCD patients. The presence of LEMGC was associated with 
extensive CD manifestation to mouth, appendix, anus or mesenterical lymph nodes in all 6 
selected pCD patients. Extensive disease manifestation was only observed in 2 out of 17 pCD 
patients without LEMGC, who suffered from anal CD. NOD2 variants where present in 2 out 
of 13 AS-P patients, both carrying R702W. EAMD was associated with R702W and early 
disease onset in classic AS-P patients. We did not find CD-associated NOD2 variants in any 
of the 10 screened AS-EP patients. Prominent EAMD was exclusively found in 1 out of 10 
screened AS-EP patients, case 23. The term adult-type PS is suitable for UPS case 8 that 
presented with LEMGC in sclerosing granulomas and had documented lung involvement. 
 
Morphological features of lymphocyte emperipolesis in MGCs 
LEMGC was usually associated with macro- (Figures R.2.3.1B and C) and microvesicles 
(Figures R.2.3.1D and E) in MGCs in all investigated diseases. Particularly in PS and AS, 
MGCs exhibiting LEMGC often had pyknotic nuclei and hypereosinophilic cytoplasm 
(Figure R.2.3.1E). Also, this observation was usually associated with fibrinoid necrosis in 
the granuloma centre and intragranulomatous fibrosis in PS and AS. MGCs with pyknotic 
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nuclei and hypereosinophilic cytoplasm were only observed in one pCD sample (case 11), 
while fibrinoid necrosis and intragranulomatous fibrosis were never observed in pCD 
granulomas. Karyorrhexis of MGCs was never observed in the investigated samples. 
Refractive crystalline inclusions in MGCs were usually present in pCD, but only sporadically 
found in PS and AS (Figure R.2.3.1F). Morphological features of lymphocyte emperipolesis 
are summarized in Table R.2.3.2. 
 
Cellular markers of lymphocytes targeted for emperipolesis in MGCs 
Lymphocytes targeted for emperipolesis in MGCs were virtually always CD4+ in the 
investigated samples (Figure R.2.3.2A). Emperipolesis of CD8+ T-lymphocytes in MGCs 
was sporadically found in PS (Figure R.2.3.2B). Emperipolesis of CD20+ B-lymphocytes in 
MGCs was never observed the investigated samples. Because IL23R was expressed by both 
lymphocytes and MGCs, it was not possible to distinguish between vesicular and cellular 
IL23R staining. In addition to granulomas found in non-lymphoid tissue, we found 
granulomas formed in the centre of lymphoid follicles in the lymph nodes of a BS (case 1), a 
NOD2+ pCD (case 10) and three AS-P patients (cases 20-22), the spleens of a BS (case 3) 
and a AS-EP (case 23) patient, the mucosa-associated lymphoid tissue (MALT) of all except 
one selected pCD patient (case 13)  and the bronchus-associated lymphoid tissue (BALT) of 
two AS-P patients (cases 17 and 22). The term granuloma-in-follicles (GIF) is used to 
describe this type of granulomas that can be objectified by CD20 staining. Cellular markers 
expressed by lymphocytes targeted for emperipolesis in MGCs are summarized in Table 
R.2.3.2. 
 
Cytokine staining pattern associated with lymphocyte emperipolesis in MGCs 
Particularly in PS and sporadically in AS and pCD, macrovesicles stained positive for IL17 
(Figure R.2.3.2C), IL6 (Figure R.2.3.2D) and TGFβ. Because TNFα, IL1β and IFNγ were 
expressed by both lymphocytes and MGCs, it was not possible to distinguish between 
vesicular and cellular staining. Furthermore, microvesicles did not show any positive 
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cytokine staining. IL10+ macrovesicles in MGCs were not observed in the investigated 
samples. The cytokine stainings associated with lymphocyte emperipolesis in MGCs are 
summarized in Table R.2.3.2. 
 
Expression of proteins involved in cell death pathways  
Particularly in PS and sporadically in AS and pCD, lymphocytes targeted for emperipolesis 
expressed FasL and MGCs exhibiting LEMGC expressed Fas. Staining for activated Caspase 
3 was never observed in either cell type. Bcl2 expression was commonly found in MGCs 
exhibiting lymphocyte emperipolesis in the investigated PS samples and sporadically found 
in the AS group. Remarkebly, Bcl2 expression of MGCs exhibiting lymphocyte 
emperipolesis was absent in the investigated pCD samples. The expression pattern of proteins 
involved in cell death pathways in MGCs are summarized in Table R.2.3.2. 
 
DISCUSSION 
 
In the present study we have attempted to describe the morphological features of and to 
identify the immune cell types involved in LEMGC in PS, pCD and AS granulomas, three 
chronic inflammatory conditions associated with NOD2 mutations. Hereto we have 
performed a morphological and immunohistochemical study of selected samples with 
granulomas exhibiting LEMGC. Emperipolesis, a term coined by Humble, Jayne and 
Pulvertaft to describe the ‘inside round about wandering’ of lymphocytes within other cells, 
13-14
 reportedly is a typical feature of sinus histiocytosis with massive lymphadenopathy 
(Rosai-Dorfman disease) and has been noted occasionally in other disorders including 
adenocarcinoma, non-hodgkin lymphoma and histiocytic carcinoma. However it has not been 
reported in adult sarcoidosis or in CD.
13-16
 We reported that LEMGC is common in PS 
granulomas and strongly associated with BS-associated mutations in NOD2. A recent article 
reported that the CD-associated R702W SNP in NOD2 was associated with severe pulmonary 
sarcoidosis.
5 
In this study, we observed LEMGC in the granulomas of 9 out of 13 AS-P 
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patients and only of 1 out of 10AS-EP patients. In both PS and AS, LEMGC was often 
detected in lymphoid tissue such as spleen, lymph nodes and BALT. Since both diseases are 
multisystemic, it is very probable that diagnostic biopsies are taken from organs or tissues 
that do not contain lymphoid tissue, for example skin biopsies, and LEMGC in granulomas is 
not observed. However, LEMGC seems to be associated with AS-P and BALT is a suitable 
target to assess the presence of GIFs and LEMGC. The diagnostic value of LEMGC might be 
higher in pCD, a chronic inflammatory disease confined to the gastro-intestinal tract. 
Intestinal biopsies often contain MALT and the presence of LEMGC and GIFs can be easily 
assessed. In pCD the link between LEMGC and GIFs was most obvious, as 11 out of 23 pCD 
patients showed GIFs in their biopsies and 5 out of 11 pCD patients with GIF exhibited 
LEMGC. Recently the link between SNPs in autophagy-related genes and NOD2 has 
attracted the attention of many investigators.
6
 The autophagy pathway is not only responsible 
for recycling on the cellular level, but also for the ingestion of micro-organisms. Furthermore 
an expansion of known NOD2 functions to autophagy induction, viral recognition and T cell 
activation has been demonstrated.
17
 We suspect that the phenomenon of LEMGC in PS, AS 
and pCD is the morphological phenotype of a disturbed interaction between the autophagy 
pathway and NOD2 function. There exists a positive feedback loop during NOD2 
stimulation: NOD2 is responsible for the induction of autophagy, while autophagosomal 
degradation products stimulate NOD2 through the antigen-presenting peptide-MHC II 
complex.
17
 It has been hypothesized that BS-associated NOD2 mutations result in a gain of 
NOD2 function and CD-associated NOD2-mutations result in loss of NOD2 function, and 
therefore one might suspect the interaction between the autophagy pathway and NOD2 is 
affected accordingly. Indeed, we observed that LEMGC is associated with MGC death 
(EAMD) in the selected PS and AS biopsies and with the formation of refractive crystalline 
inclusions in MGCs (EACI) in the selected pCD biopsies. The observation of EACI in the 
selected pCD samples suggests autophagy can be initiated, but evokes a compromised 
response that attenuates the feedback loop. This delayed and indecisive stimulation of the 
innate immunity probably leads to increased longevity of MGCs and the accumulation of 
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autophagosomes that might be the substrate for the formation of refractive crystalline 
inclusions. The presence of EACI in pCD granulomas has to be interpreted in a polygenic and 
multifactorial context. Although the CD-associated NOD2 SNP R702W has been associated 
with severe pulmonary sarcoidosis, granulomatous inflammation is clearly more extensive in 
AS than in CD. This suggests loss-of-function of NOD2 due to R702W pathogenically 
contributes less to AS than to CD. Furthermore, we observed EAMD more often than EACI 
in the selected AS biopsies, as in PS. Refractive crystalline inclusions, called Schaumann 
bodies in sarcoidosis, were only sporadically found in BS case 3 and AS-P cases 16 and 21. 
In cases 3 and 21, Schaumann bodies were sporadically present in these two biopsies that 
predominantly exhibited EAMD. Case 16’s renal biopsy was the only selected AS sample 
that exclusively exhibited EACI in the granulomas. Furthermore, it was the only AS-P patient 
with a CD8 over CD4 predominance in the chronic inflammatory infiltrate, suggesting 
granuloma formation in a context of immune deficiency. Interestingly, Ochratoxine A 
inhalation was suspected but never proven to be the cause of this patient’s renopulmonary 
sarcoidosis due to its known nephrotoxic and immunotoxic effect.
18
 Possibly, LEMGC is the 
microscopic phenotype of excessive stimulation of the autophagy pathway in granulomas of 
BS patients with NOD2 hyperactivity, ultimately leading to atypical death. In contrast, 
sequestered autophagy products might be the ideal substrate for Schaumann body formation 
in (pCD) and AS patients with lethargic macrophages rendered insensitive to (alternative) 
death cues. The biochemical composition of Schaumann bodies has been determined by Reid 
and Andersen as mainly calcium oxalate.
19
 Hypercalcemia has been associated with renal 
sarcoidosis.
20
 Granuloma formation has been related to a failure of the innate immune system. 
One of the possible explanations is a vitamin D deficiency resulting in calcium metabolism 
impairments. The combination of a substrate with high calcium levels might result in 
Schaumann bodies. CD has been called a primary immune deficiency of the macrophage as 
well. The autosomal dominant inheritance pattern, the monogenic etiology and the early age 
of disease onset in BS demonstrate BS-associated NOD2 mutations result in granulomatous 
auto-inflammation due to a gain of NOD2 function. This is further demonstrated 
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pathologically by the auto-inflammatory signature observed in BS granulomas: polycyclic 
granuloma architecture with dense lymphocytic coronas, IL17 expression and EAMD. It 
remains enigmatic which type of cell death EAMD is. The presence of nuclear shrinkage 
(pyknosis) without nuclear fragmentation (karyorrhexis) in MGCs is typical for caspase-
independent cell death (CICD).
21
 Immunohistochemical staining could not demonstrate 
Caspase 3 activation in MGCs exhibiting LEMGC. Furthermore, autophagic vacuolization 
(macrovesicles) with autophagosome accumulation (microvesicles) is characteristic for CICD 
as well. Cytoplasmic condensation (hypereosinophilia) is more characteristic for apoptosis 
than CICD, but was also often observed in MGCs exhibiting EAMD. CICD occurs in 
response to most intrinsic apoptotic cues, provided that mitochondrial outer membrane 
permeabilization (MOMP) has occurred. Expression of the anti-apoptotic and anti-autophagic 
protein Bcl2 prevents MOMP
22
 and was often observed in MGCs exhibiting EAMD in PS 
and AS, but not pCD samples. Death receptor ligation can also trigger a form of CICD 
termed necroptosis, a process in which the downstream effector of NOD2, receptor 
interacting protein 2 (RIP2), plays a key function.
21
 In the selected PS samples in particular, 
we observed Fas expression in MGCs exhibiting LEMGC and FasL expression in 
emperipoletic lymphocytes. IL1β expression in MGCs suggests inflammasome activation, 
required for pyroptosis. Most likely exaggerated autophagy, granuloma persistence and 
cytokine production result in the accumulation of pro-necroptotic and/or pro-pyroptotic cues 
that eventually trigger EAMD in MGCs exhibiting LEMGC. Although further investigation is 
needed to dissect the role of the different pathways contributing to EAMD, we suspect it is a 
form of CICD associated with granulomatous auto-inflammation. We observed that CD4+ T-
lymphocytes were selectively ingested by MGCs, suggesting this is not a cytotoxic response 
of CD8+ T-lymphocytes. Ingestion of CD20+ B-lymphocytes was not observed. Macro- and 
microvesicles and degenerative remnants inside MGCs stained positive for IL6 and IL17, and 
sporadically for TGFβ. These data suggest CD4+ Th17-lymphocytes are the principal target 
for LEMGC.  
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Table R.2.3.1. Summary of the patients’ gender, age at onset, outcome of LEMGC, NOD2 status, 
diagnostic biopsy site available for examination of granulomas for each individual case exhibiting 
LEMGC in granulomas seen in the available biopsy tissue. (BS: Blau syndrome; UPS: unclassified 
pediatric sarcoidosis; pCD: pediatric Crohn’s disease; AS-(E)P: adult (extra-)pulmonary sarcoidosis.) 
 
 
Patient Diagn. Sex Onset  Outcome NOD2 variants Diagn. Biopsy Site(s) 
Case 1 BS ♂ 2y EAMD R334Q (HE) Lymph node 
Case 2 BS ♂ 4y - R334W (HE) Synovium 
Case 3 BS ♂ 1y EAMD/CI G481D (HE) Spleen 
Case 4 BS ♂ 1y EAMD L454V (HO) Bone marrow (2) 
Case 5 BS ♀ 1y EACI R334W (HE) Synovium 
Case 6 UPS ♂ 8y EAMD wt Liver (3) 
Case 7 UPS ♂ 17y - G908R (HE) Lymph node 
Case 8 UPS ♂ 15y - ? Kidney 
Case 9 pCD ♀ 18y EACI G908R (HE) Appendix 
Case 10 pCD ♀ 9y EACI R702W(HE),  
L1007fsinsC-/C (HE) 
Anus, Colon, Ileum, Lymph 
node 
Case 11 pCD ♀ 14y EAMD/CI wt Mouth 
Case 12 pCD ♂ 15y - wt Appendix 
Case 13  pCD ♀ 14y EACI wt Ileum 
Case 14 pCD ♂ 14y - wt Colon 
Case 15 AS-P ♀ 33y - R702W (HE) Liver 
Case 16 AS-P ♂ 26y EACI wt Kidney 
Case 17 AS-P ♀ 62y EAMD wt Lung 
Case 18 AS-P ♂ 24y EAMD wt Lung 
Case 19 AS-P ♂ 45y EAMD R702W (HE) Lung 
Case 20 AS-P ♂ 45y EAMD wt Lymph node 
Case 21 AS-P ♂ 61y EAMD/CI wt Lymph node 
Case 22 AS-P ♀ 36y EAMD wt Bronchus, Lymph node 
Case 23 AS-EP ♀ 36y EAMD wt Spleen 
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Table R.2.3.2. Morphological and immunohistochemical features of LEMGC in the selected PS, 
pCD and AS patient groups were semiquantitatively scored: - absent; + sporadic; ++ common; +++ 
prominent. Adjusted patient counts are between brackets. (PS: pediatric sarcoidosis; pCD: pediatric 
Crohn’s disease; AS: adult sarcoidosis; TL: T-lymphocytes; MGC: multinucleated giant cell.) 
 
 
Emperipolesis in MGCs in PS pCD AS 
Presence of NOD2 variants +++ + + 
Occurrence per case ++ + + 
Morphology N=8 N=6 N=9 
Pyknosis ++ + ++ 
Karyorrhexis - - - 
Hypereosinophilia ++ + ++ 
Macrovesicles ++ + + 
Microvesicles ++ ++ ++ 
Refractive Inclusions + ++ + 
Fibrinoid Necrosis ++ - + 
Intragranulomatous Fibrosis ++ - + 
Immunohistochemistry N=6 N=6 N=9 
Emperipolesis of CD4+ TL +++ +++ +++ 
Emperipolesis of CD8+ TL + - - 
Emperipolesis of CD20+ TL   -  (n=5) - - 
Emperipolesis of IL23R+ TL NA NA NA 
TNFα+ Macrovesicles NA NA NA 
IL1β+ Macrovesicles NA NA NA 
IL6+ Macrovesicles ++ (n=5) + + 
IL10+ Macrovesicles -   (n=5) - - 
IL17+ Macrovesicles ++ + + 
TGFβ+ Macrovesicles + (n=5) + - 
IFNγ+ Macrovesicles NA NA NA 
Bcl2+ MGCs ++ - + 
Fas+ MGCs ++ (n=5) + + 
Emperipolesis of FasL+ TL ++ (n=5) + + 
Activated Caspase 3+ MGCs -  (n=5) - + 
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Figure R2.3.1. H&E staining of lymphocyte emperipolesis in multinucleated giant cells in 
granulomas A) emperipolesis of a lymphocyte at the border of a MGC ; B) autophagic vacuoles 
(macrovesicles) containing basophilic nuclear remnants are transported to the centre of a MGC; C) 
central collection of macrovesciles surrounded by accumulating microvesicles;  D) autophagosome 
accumulation (microvesicles) in the centre of a MGC; E) a MGC exhibiting LEM  is filled with 
microvesicles beyond the MGC centre and has pyknotic nuclei and hypereosinophilic cytoplasm, but 
no nuclear fragmentation; F) a Schaumann body in the centre of a MGC filled with microvesicles. 
(x1000) 
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Figure R2.3.2. Immunohistochemistry of lymphocyte emperipolesis in multinucleated giant cells 
show A) CD4+ T-lymphocytes are the primary target of LEMGC (x400); B) LEMGC of CD8+ T-
lymphocytes was only sporadically observed (x400); C) LEMGC with vesicular staining of IL17 in the 
MGC centre, were autophagic vacuoles (macrovesicles) are collected (x200);  D) LEMGC with 
vesicular staining of IL6 in the MGC centre (x400). 
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APPENDIX I: Case Report   
As described earlier, the Blau Registry, which recruits data from children and families with 
granulomatous inflammatory conditions worldwide, attracts a variety of candidate patients 
with enigmatic (granulomatous) inflammatory disorders. Inclusion in the BCS necessitates 
the documentation of granulomas in any affected organ tissue and whole NOD2 gene 
sequencing performed on all selected (PS) patients. The diagnosis of BS depends on the 
detection of a known or novel NOD2 mutation. To reduce the complexity of this manuscript, 
we decided to focus on international PS patients genotyped through the Blau Registry (BS, 
IOPSG or UPS) and restrospectively selected local UPS patients with granulomatous 
inflammation. The CGD and CHH cases were the only mutation-proven primary ID patients 
exhibiting granulomatous inflammation in children.Among many other investigated cases, we 
decided one peculiar case was worth reporting. The isolated hepatic PS case LEUVEN.6.P 
published in this chapter presented with a Budd Chiari syndrome as an 8 year old child 
without suspicion of hereditary disease or clues in the literature; his genotype was not further 
investigated. PS set on during adolescence in 3 other unclassified PS patients and therefore 
they were not considered for further genotyping either. Although this patient did not carry 
any disease associated SNPs in NOD2, LEMGC associated with atypical MGC death was 
observed on a liver punction biopsy taken upon presentation, in the explanted liver and a third 
time on a liver punction biopsy taken for follow-up 6 years later, before the start of 
corticosteroid immune suppression. In this case the histopathological phenotype of LEMGC 
could have had diagnostic value when the boy initially presented with Budd Chiari and 
isolated liver sarcoidosis. The case presented here is included in this manuscript because it 
could be used as an argument for the diagnostic use of the feature of emperipolesis for 
granulomatous auto-inflammation in the future. We would like to refer to the general 
discussion for more elaborate argumentation to support this cue. 
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APPENDIX II: Pediatric sarcoidosis cases  
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APPENDIX III: Pediatric Crohn’s disease cases  
  
Patient Diagnosis Sex Onset Age NOD2 BS NOD2 CD Granuloma Biopsy site 
Case 1 pCD (GIF) F 9y NA R702W (HE), 
L1007fsinsC-/C (HE) 
Anus, colon, ileum, lymph 
node, rectum 
Case 2 pCD M 16y NA  Colon 
Case 3 pCD M 13y NA  Colon 
Case 4 pCD M 9y NA  Oesophagus, stomach, skin 
Case 5 pCD (GIF) F 14y NA  Colon, ileum, mouth,stomach 
Case 6 pCD F 14y NA  Duodenum, ileum, stomach 
Case 7 pCD M 18y NA L1007fsinsC-/C (HE) Ileum 
Case 8 pCD (GIF) F 17y NA L1007fsinsC-/C (HO) Colon 
Case 9 pCD M 14y NA  Stomach 
Case 10 pCD F 18y NA R702W (HE), 
L1007fsinsC-/C (HE) 
Ileum 
Case 11 pCD (GIF) M 14y NA  Anus, rectum 
Case 12 pCD M 17y NA  Stomach 
Case 13 pCD (GIF) F 14y NA R702W (HE) Stomach, colon 
Case 14 pCD (GIF) F 18y NA G908R (HE) Appendix 
Case 15 pCD (GIF) M 15y NA  Appendix, ileum, lymph node 
Case 16 pCD (GIF) F 13y NA  Colon, ileum, stomach 
Case 17 pCD M 13y NA L1007fsinsC-/C (HE) Colon 
Case 18 pCD M 19y NA  Colon 
Case 19 pCD M 15y NA  Colon, ileum 
Case 20 pCD (GIF) M 15y NA  Ileum, stomach 
Case 21 pCD M 16y NA  Colon 
Case 22 pCD (GIF) M 14y NA  Colon 
Case 23 pCD (GIF) F 14y NA  Colon, ileum 
Appendix Table 2. An overview of all 23 histopathologically characterized pCD cases that were 
investigated in Results Chapters 1.2 and 2.1 and genotyped for 3 CD-associated SNPs in NOD2 only. 
These patients were not checked for the most common BS mutation R334W/Q. NA= not applicable. 
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APPENDIX IV: Adult sarcoidosis cases  
 
Patient Diagnosis Sex Onset Age NOD2 BS NOD2 CD Granuloma Biopsy site 
A1 AS-EP F 36y NA  Liver, spleen 
A2 AS-EP F 63y NA  Skin 
A3 AS-EP M 25y NA  Epididimis 
A4 AS-EP M 49y NA  Liver (2) 
A5 AS-P F 33y NA R702W (HE) Liver 
A6 AS-P F 25y NA NA Liver 
A7 AS-EP M 64y NA  Kidney 
A8 AS-EP M 74y NA  Kidney 
A9 AS-EP F 76y NA NA Kidney 
A10 AS-EP M 59y NA  Kidney 
A11 AS-EP M 63y NA  Kidney 
A12 AS-P M 26y NA  Kidney 
A13 AS-P F 62y NA  Lung, pleura 
A14 AS-P M 24y NA  Lung 
A15 AS-P M 45y NA R702W (HE) Lung (2), heart 
A16 AS-P M 71y NA  Lymph node 
A17 AS-P M 45y NA  Lung, lymph node(4) 
A18 AS-P M 61y NA  Lung, lymph node(3) 
A19 AS-P F 36y NA  Bronchus, lung, lymph node, 
skin 
A20 AS-P F 73y NA  Lymph node 
A21 AS-P F 53y NA  Bronchus, lymph node 
A22 AS-P M 55y NA  Kidney, lymph node 
B1 AS-EP M 42y NA L1007fsinsC-/C (HE) Liver 
B2 AS-P M 35y NA  Liver 
B3 AS-P F 33y NA R702W (HE) Liver, spleen 
B4 AS-P F 70y NA  Bronchus, liver 
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B5 AS-EP M 27y NA R702W (HE) Liver 
B6 AS-P F 58y NA  Kidney (2) 
B7 AS-P M 78y NA  Kidney, vitreal fluid 
B8 AS-P F 35y NA  Bronchus, bone marrow, 
subcutis, spleen (2) 
B9 AS-P F 67y NA  Lymph node 
B10 AS-P M 41y NA  Bronchus 
B11 AS-P F 57y NA  Bronchus, lung 
B12 AS-P M 48y NA  Lung 
B13 AS-P M 81y NA  Lung, lymph node 
B14 AS-P M 41y NA  Lung (2), lymph node 
B15 AS-P M 26y NA R702W (HE) Lymph node 
B16 AS-P M 28y NA R702W (HE) Lymph node 
B17 AS-P F 62y NA  Bronchus, lymph node (2) 
B18 AS-EP M 29y NA G908R (HE) Heart, pacemakerlead 
B19 AS-P M 60y NA  Bone marrow, heart, kidney, 
liver (2), lung 
B20 AS-P F 64y NA R702W (HE) Liver, lung 
B21 AS-EP M 50y NA  Bone marrow, kidney, liver (3) 
 
Appendix Table 3. An overview of patients’ diagnosis, sex, onset age,  NOD2 status and granuloma 
biopsy site(s) in 22 histopathologically characterized AS cases that were initially selected (A1-A22) or 
part of the expanded selection (B1-B21) were investigated in Results Chapter 2.2 and genotyped for 3 
CD-associated SNPs in NOD2 only. These patients were not checked for the most common BS 
mutation R334W/Q. NA= not applicable. 
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GENERAL DISCUSSION  
This doctoral work started with the histopathological study of the BS, an extremely rare 
granulomatous disease in children with a genetic defect in the NOD2 gene. Since the Genetic 
Revolution in biomedical research worldwide is attracted by exploring hypothetical links 
between genetic variants, functional consequences (e.g. loss-of-function, gain-of-function), 
morphologic and histopathologic characteristics, molecular and inflammatory pathways 
involved in the expression of inflammatory cytokines, and finally, the subsequent clinical 
features and syndromes. On the crossroads of all these points of view reside the ultimate 
questions: what is relevant for the patient, in terms of therapy, genetic counselling, evolution 
and prognosis, and secondly, what is relevant for the physician, namely, what is relevant for 
the diagnosis, therapy and follow up. After the setting-up of a database for BS patients, the 
morphologic exploration of BS granulomas in particular, and other granulomas in general, 
needed a refinement of morphologic definition and, at least in an experimental setting, a 
better definition of observed morphologic features. This is the subject of Results Section 1.
1
 
Basically, herein described granuloma stages and phases are connected, as shown in Table 1. 
Moreover, our morphologic investigation, innovative in a sense that new morphologic aspects 
are highlighted in the setting of different granulomatous inflammatory diseases, revealed 
LEMGC in polycylic granulomas with lymphocytic coronas are prominent in auto-
inflammatory BS granulomas and GIF can occur in different settings of granulomatous 
inflammation. Emperipolesis is a morphologic feature characteristic of sinus histiocytosis 
with massive lymphadenopathy a.k.a. RDD. GIF can be observed in the follicle centre of 
secondary lymphoid tissue associated with the bronchi, gut or found in lymph nodes and/or 
spleen tissue. In a second step, BS granulomas were compared to the granulomas observed in 
other PS cases. This study is briefly presented in Results Chapter 2.1, which focuses more on 
the comparison between granulomas in BS and NOD2+ pCD. Granulomas in NOD2- pCD 
did not differ significantly from granulomas in NOD2+ pCD, although the latter was 
associated with increased sclerosis of the surrounding tissue, a morphologic feature 
compatible with the stenotic subtype of CD. The most striking histopathological differences 
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were observed when granulomas in BS and NOD2+ pCD were compared.
2
 They were 
interesting indeed, because BS is a systemic granulomatous disease caused by gain-of-
function mutations in NOD2. CD is associated with intestinal granulomas and loss-of-
function NOD2 variants. The hypothesized mechanisms of contribution of different NOD2 
variants to distinct disease phenotypes was also reflected on the cytokine level as IL17 was 
prominent in BS granulomas and only seen with GIF in pCD.
3
 The pathological BS triad of 
auto-inflammatory granuloma features (LEMGC, polycyclica granuloma architectire and 
Th17 involvement) was completed by adding this IHC staining for IL17, a cytokine 
associated with auto-immunity and granulomatous inflammation. We looked for this 
pathological BS triad of auto-inflammatory granuloma features in following studies.  
First, we looked for the peculiar characteristics of BS granulomas in AS patients and 
genotyped them for three CD-associated NOD2 variants. Entire NOD2 gene sequencing of 
individual AS patients was not financially feasible, but might reveal more if specific AS 
subtypes are selected to look for the occurance of BS mutations or former non-disease 
associated SNPs in NOD2. We found LEMGC and IL17 expression to be associated with 
classic AS-P with sclerosing aggregates of granulomas. Although polycyclic granuloma 
architecture and lymphocytic coronas were often observed with the other 2 features, they 
were only sporadically the predominant histologic phenotype in AS patients. We could 
confirm NOD2 variant R702W is associated with severe AS-P, as reported by Sato et al in 
2010.  
Second, we have attempted to describe the possible outcomes of LEMGC in NOD2-related 
granulomatous inflammatory diseases, initially only BS and pCD, and later also AS. Chapter 
2.3 focusses on the outcome of lymphocyte emperipolesis in three NOD2-related 
granulomatous diseases
4
 described in the previous two chapters of Section 2, in the light of 
the loss/gain-of-function hypothesis of CD/BS-associated NOD2 variants and the NOD2-
autophagy pathway. The refractive crystalline inclusions a.k.a. Schaumann bodies might 
result from sequestered autophagy products accumulating in MGCs with the loss-of-function 
phenotype. We observed these bodies in both pCD and AS granulomas of patients with GIF. 
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Massive lymphocyte emperipolesis associated with caspase3-independent MGC death in BS 
can then be interpreted as a result of gain-of-function and kill-switch of MML hyperactivity.  
Caspase3-mediated death was found with LEMGC in palisading granulomas with necrosis in 
CHH exhibiting GIF and wild type NOD2.
5
 On the other hand, the case of isolated hepatic 
sarcoidosis recurring after liver transplantation showed LEMGC but not GIF in the intestine 
that was extensively examined and sampled using endoscopy.
6
 The presence of GIF could 
have had prognostic value for opportunistic infection when they were noted in the initial 
endoscopic biopsies of the gut of the CGD patient. Further molecular studies empirically 
designed to unravel the underlying functional mechanisms are necessary to collect additional 
argumentation. Lately more scientific evidence is emerging to support the hypothesis of 
pulmonary-intestinal cross-talk in mucosal inflammatory disease.
7
  
The respiratory and gastro-intestinal tracts share a common physiology as they are the first 
barrier against internalized environmental particles and both originate from the primitive 
foregut embryonically.
8, 9
 During the siege of the human body, both organ systems are walled 
by epithelium that is defended by tissue-specific innate immune cells and towered by 
bronchus- or mucosa- associated lymphoid tissue respectively. Innate immune cells sense, 
clear and sample environmental particles they encounter while defending the epithelium and 
adaptive immune cells select, multiply and recognize to optimize the defence for future 
encounters with the identified insult. Three things are of major importance for optimal first 
line defence: epithelial barrier, innate immunity and immunologic synapse. Regarding all 
three aspects, clinical similarities can be found between the respiratory and gastrointestinal 
diseases. Epithelial barrier disruption is believed to contribute to astma and colitis ulcerosa, 
affecting the lung and gut respectively. In this manuscript, innate immune defects due to a 
complex genotype-phenotype interaction are associated with eptihelioid granulomas in classic 
AS-P and CD in the lung and gut respectively.  
Finally we described the peculiar phenotype of GIF in BALT/mediastinal lymph nodes and 
MALT/mesenteric lymph nodes and associated it with extensive granulomatosis during the 
course of this research. Because granulomatous inflammation is archaically interpreted as a 
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result of frustrated phagocytosis, GIF can be interpreted as frustrated immunologic synapse 
communication. Autophagy attenuates the adaptive immune response by destabilizing the 
immunologic synapse as recently reported.
10 
Possebly, lymphocyte emperipolesis and 
sequestration of autophagy products are signs of frustrated innate immune function and 
immunologic synapse communication in CD and AS. GIF are specifically associated with 
extensive disease manifestation and Th17 involvement, indicating the immunologic synapse 
and possibly also immune cell homing are crucial for exacerbation of inflammation (Th17 
activation) and extension of disease manifestation. Furthermore there seems to be an 
important interaction between the respiratory and intestinal microbiomes: smoking 
contributes both to the development of chronic obstructive pulmonary disease and 
inflammatory bowel disease, possibly due to its pro-inflammatory properties (reactive oxygen 
species) and the selection of smoke-resistant Gram negative bacilli.
11, 12
 We specifically 
observed GIF in pCD at sites with an alternative microflora (os, appendix, anus). 
In both CD and AS, the patient population seems to be made up of two epidemiologically 
distinguishable curves: variants in genes crucial for innate immune function contribute more 
to pCD than to adult CD. Also in sarcoidosis, the contribution of genetic variants such as 
Blau mutations is greater in PS than in AS. It seems logical that genetic susceptibility to 
develop a disease is present since birth and is therefore more likely to affect the patient at a 
younger age than acquired susceptibility due to smoking or changes in the microbiome in 
older patients.  
Although only a minority of patients worldwide is affected by an orphan disease, hence the 
name, they are of intrest because they are naturally occurring (monogenetic) study models in 
humans, or ‘experiments of nature’, as the well-known hepatologist Hans Popper used to call 
them.
14
 For BS in particular, a viable mouse model could not be developed yet. Attentive 
observation, detailed description and alternative financial support are crucial to collect a 
statistically relevant amount of patients suffering from such rare orphan diseases as the BS or 
6IOPSG worldwide. If this is achieved, using laboratory animals for research is needed less.  
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Although we managed to recognize differences in the microscopical granuloma phenotype of 
clinically distinct NOD2-related diseases, we were not able to identify the exact mechanism 
of emperipolesis-associated MGC death yet. Here we only describe this phenomenon to be 
associated with terminal stage granulomas and we tried to collect evidence to support its 
diagnostic and prognostic relevance for idiopathic granulomatous inflammatory diseases in 
children and adults. Our data included genetical, clinical, histopathological and 
demographical parameters and were collected in a uniform manner to ensure comparability 
and enable scientific reproducibility. We are at the start of a new era studying the link 
between genotype and clinical phenotype. 
In conclusion, our studies yield a refined description of epithelioid granulomas and their 
formation, including new features of LEMGC, GIF, Th17 involvement and polycyclic 
granuloma architecture. The latter features are likely to have either prognostic or diagnostic 
relevance. More importantly, there descriptive value may serve as a backbone for further 
“structure-function” studies. 
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SUMMARY   
 
The Blau Syndrome (BS) is a type of pediatric sarcoidosis (PS) caused by gain-of-function 
mutations in NOD2, an intracellular pathogen sensor protein expressed by innate immune 
cells. BS is a rare orphan disease characterized by a clinical triad of granulomatous auto-
inflammation in the skin, joints and eyes, and the entire body. BS patients provide a naturally 
occurring study model for granulomas in humans. We described pathognomonic features of 
granulomatous auto-inflammation in BS. NOD2 induces inflammation, autophagy, antigen-
presentation and death pathways. We used a standardized set of morphological and 
immunohistochemical (leukocyte markers HLA-DR, CD68, CD4, CD8, CD20, IL23R; 
cytokines TNFa, IFNg, IL1b, IL6, IL10, IL17, TGFb and death related proteins Bcl2, Fas, 
FasL, activated Caspase3) features to investigate granulomas in 54 biopsies of 19 PS, 37 
biopsies of 23 adult sarcoidosis (AS) and 57 biopsies of 23 pediatric Crohn’s disease (pCD) 
patients. Emperipolesis-associated multinucleated giant cell (MGC) death (EAMD), 
polycyclic granulomas with lymphocytic coronas and Th17 involvement were typically seen 
in BS biopsies. In AS patients, EAMD and Th17 involvement were found in classic 
pulmonary sarcoidosis of the sclerosing type. In pCD patients EAMD, polycyclic granulomas 
and Th17 involvement were occasionally seen in patients with granulomas-in-follicles (GIF). 
GIF are granulomas that are formed in the follicle centre of secondary lymphoid tissue in the 
gut (mucosa-associated lymphoid tissue), lung (bronchus-associated lymphoid tissue), spleen 
and lymph nodes. GIF were also found in AS patients exhibiting features of granulomatous 
auto-inflammation. Unlike BS mutations, loss-of-function SNPs in NOD2 were not 
associated with EAMD, Th17 involvement or polycyclic granulomas in pCD or AS. The 
pathological features of granulomatous auto-inflammation in BS can be of diagnostic use for 
idiopathic granulomatous inflammation in children and adults. The detection of GIF is 
associated with increased disease morbidity in PS/CD/AS. 
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SAMENVATTING  
 
Het Blau Syndrome (BS) is een type pediatrische sarcoidosis (PS) veroorzaakt door 
activerende mutaties in NOD2, een intracellulaire pathogeen-sensor geëxprimeerd door 
aangeboren immuuncellen. BS is een zeldzame weesziekte gekarakterizeerd door een 
klinische triade van automatische granulomateuze ontsteking in de huid, gerwrichten en ogen, 
en het gehele lichaam. BS patiënten bieden ons een natuurlijk voorkomend studiemodel van 
granulomas in de mens. We beschreven pathognomonische kenmerken van automatische 
granuloma-teuze ontsteking in BS. NOD2 induceert ontsteking, autophagie, antigen-
presentatie en celdood. We gebruikten een vast pannel van morfologische en 
immuunhistochemische (witte bloedcel merkers HLA-DR, CD68, CD4, CD8, CD20, IL23R; 
cytokines TNFa, IFNg, IL1b, IL6, IL10, IL17, TGFb en celdood proteïnen Bcl2, Fas, FasL en 
geactiveerd Caspase3) kenmerken om granulomas te onder-zoeken in 54 biopsies van 19 PS, 
37 biopsies van 23 adulte sarcoidosis (AS) en 57 biopsies van 23 pediatrische ziekte van 
Crohn (pCD) patiënten. Emperipolesis-geassocieerde celdood van meerkernige reuscellen 
(EAMD), polycyclische granulomas met lymphocyten-kronen en Th17 werden typisch gezien 
in BS biopsies. In AS patiënten, EAMD en Th17 werden gevonden in klassieke 
longsarcoidose van het scleroserende type. In pCD patiënten werden EAMD, polycyclische 
granulomas en Th17 betrokkenheid soms gezien in patiënten met granuloma-in-follikels 
(GIF). GIF worden gevormd in het follikel-centrum van secundair lymfoid weefsel in de 
darm (mucosa-geassociëerd lymfoid weefsel), long (bronchus-geassocieerd lymfoid weefsel), 
milt en lymfeklieren. GIF werden ook gevonden in AS patiënten met kenmerken van 
automatische granulomateuze ontsteking. In tegenstelling tot BS mutaties, waren 
inactiverende SNPs in NOD2 niet geassociëerd met EAMD, Th17 of polycyclische 
granulomas in pCD of AS. De pathologische kenmerken van automatische granulomateuze 
ontsteking in BS kunnen van diagnostisch belang zijn voor idiopathische granulomateuze 
ontsteking in kinderen en volwassenen. 
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